REVIEW

[View Article Online](#)
[View Journal](#) | [View Issue](#)

Cite this: *Food Funct.*, 2021, **12**, 12194

Beneficial effects of cinnamon and its extracts in the management of cardiovascular diseases and diabetes†

Chang Shang,^{‡a,b} Hongchen Lin,^{§a,b} Xuqin Fang,^{§a,b} Yuling Wang,^{a,b} Zhilin Jiang,^a Yi Qu,^{a,b} Mi Xiang,^a Zihuan Shen,^{a,b} Laiyun Xin,^{a,c} Yingdong Lu,^a Jialiang Gao^{*a} and Xiangning Cui^{id*a}

Cardiovascular diseases (CVDs) and diabetes are the leading causes of death worldwide, which underlines the urgent necessity to develop new pharmacotherapies. Cinnamon has been an eminent component of spice and traditional Chinese medicine for thousands of years. Numerous lines of findings have elucidated that cinnamon has beneficial effects against CVDs in various ways, including endothelium protection, regulation of immune response, lowering blood lipids, antioxidative properties, anti-inflammatory properties, suppression of vascular smooth muscle cell (VSMC) growth and mobilization, repression of platelet activity and thrombosis and inhibition of angiogenesis. Furthermore, emerging evidence has established that cinnamon improves diabetes, a crucial risk factor for CVDs, by enhancing insulin sensitivity and insulin secretion; regulating the enzyme activity involved in glucose; regulating glucose metabolism in the liver, adipose tissue and muscle; ameliorating oxidative stress and inflammation to protect islet cells; and improving diabetes complications. In this review, we summarized the mechanisms by which cinnamon regulates CVDs and diabetes in order to provide a theoretical basis for the further clinical application of cinnamon.

Received 19th June 2021,
Accepted 2nd November 2021

DOI: 10.1039/d1fo01935j

rsc.li/food-function

1. Introduction

Cardiovascular diseases (CVDs) and diabetes are the leading causes of death worldwide.¹ According to the statistics of the American Heart Association, the prevalence of heart disease in 2017 was 10.6%, and it is reported that 17.8 million people died from CVDs in this year.^{2,3} Diabetes may result in many types of complications, and cardiovascular complications are the main cause of morbidity and mortality in diabetic patients.¹ Currently, various types of Western medicine, such as hypoglycaemic drugs, antihypertensive drugs, statins, and anticoagulants, have been developed. However, the side effects and medication adherence remain concerns.^{4,5} In recent years, increasingly more attention has been given to the treatment of

CVDs and diabetes with traditional Chinese medicine. Herbal medicine could improve the surrogate endpoints of CVD, including blood pressure, electrocardiogram changes or left ventricular function and/or drug-related adverse reactions; and Herbal medicine is considered to be a substitute and supplementary method for the primary and secondary prevention of CVD.⁶ Traditional Chinese medicine has also been reported to play a more important role in fighting diabetes.⁷

Cinnamon, a common spice, is an herbal medicine and an anti-inflammatory dietary supplement recommended for the primary and secondary prevention of coronary artery disease.⁸ Furthermore, cinnamon has been found to decrease fasting blood glucose (FBG) and homeostatic model assessment for insulin resistance (HOMA-IR) level, thus bringing benefits to diabetic patients.^{9,10} The genus *Cinnamomum*, also known as cinnamon (Fig. 1), is a small tropical tree of the lauraceae family. There are approximately 250 species of *Cinnamomum*; and the plant was originally grown in Sri Lanka, East and Middle Asia.^{11,12} Essential oils made from cinnamon are also widely used in the food and cosmetic industries.¹³ A plethora of studies have deeply explored the active ingredients and therapeutic effects of cinnamon. Numerous studies have revealed that cinnamon has neuroprotective, lipid-lowering, antioxidant, anti-inflammatory, and hypoglycaemic effects,

^aGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. E-mail: cuixiangning@126.com, lianggaonmg@163.com

^bBeijing University of Chinese Medicine, Beijing, 100029, China

^cFirst Clinical Medical School, Shandong University of Chinese Medicine, Shandong, 250355, China

†Electronic supplementary information (ESI) available. See DOI: 10.1039/d1fo01935j

‡First author.

§ Co-first author.

(a)

(b)

Fig. 1 The whole plant of *Cinnamomi Cortex* (a). Traditional Chinese herb Rougui and cinnamon powder (b).

some of which are closely related to the development of diabetes and CVDs.^{13–18} In this review, we provide a comprehensive overview of the therapeutic potential and possible mechanisms of cinnamon in treating diabetes and CVDs.

2. Chemical constituents and pharmacological features of cinnamon

The German Commission E and the European Scientific Cooperative on Phytotherapy (ESCOP) approved two types of

cinnamon for herbal use: *Cinnamomum* (C.): *C. zeylanicum* and *C. cassia*.¹⁹ The bark of cinnamon can be peeled and dried in shade to produce Chinese medicine, which can treat chest pain, abdominal pain and dysmenorrhea. Pharmaceutical manufacturers often use Ceylon cinnamon and Chinese cinnamon to produce cinnamon oil, which is absorbed into the body through the skin or olfactory system to play a therapeutic role, for aromatherapy.^{13,20,21} Different types of cinnamon extracts, such as the methanolic crude extracts of *C. verum*, the *C. zeylanicum* Blume essential oil, the ethanol extracts of cinnamon bark, and cinnamon bark aqueous extract, all exhibit antioxidant activity, which indicates the potential of cinnamon to treat oxidative stress-related diseases.^{22–25}

More than 80 compounds were separated and characterized from different parts of cinnamon. The major compounds of cinnamon include eugenol, cinnamaldehyde, camphor, cinnamyl acetate, and copane, as well as other minor constituents (Fig. 2). Eugenol has been reported to be a major component of leaf oil; cinnamaldehyde and camphor were found to be the major compounds of stem bark and root bark volatile oils, respectively; and *trans*-cinnamyl acetate was identified as a major compound in fruits, flowers, and fruit stalks.¹²

C. zeylanicum bark essential oil can scavenge free radicals, inhibit the oxidation of β -carotene to play an antioxidant role, and has a dose-dependent antiproliferative effect on adipose-derived mesenchymal stem cells, which makes *C. zeylanicum* bark essential oils have the potential to develop medical treatments.²¹ Thirteen compounds were extracted from the essential oil of *C. zeylanicum* Blume bark, of which (*E*)-cinnamaldehyde accounted for 97.7%.²⁶ Cinnamaldehyde has been revealed to exert antioxidation, anti-inflammatory, blood vessel protection and hypoglycaemic and antibacterial effects.^{27–30} The main component of cinnamon leaf essential oil is eugenol.¹⁹ Nineteen ingredients were extracted from the volatile oil of *C. zeylanicum* Blume leaves, and eugenol accounted for 87.3%.²⁶ Eugenol showed very powerful activities of inhibiting peroxynitrite-induced lipid peroxidation.³¹ *Trans*-Cinnamaldehyde and *D*(+)-camphor are the most important compounds in the essential oils extracted from the leaves of two *C. osmophloeum* clones and could be applied as nutraceuticals or antioxidant remedies with their antioxidant effects.³² *Trans*-Cinnamaldehyde has also been found to possess substantial antimicrobial, anticancer and anti-inflammatory properties.^{33,34} *Trans*-Cinnamaldehyde, *T*-cadinol and α -cadinol obtained from the essential oils of *C. osmophloeum* leaves could strongly inhibit nitric oxide (NO) production and have excellent anti-inflammatory activities, thus having great potential as a source for natural health products.³⁵ The phenolic constituents extracted from the fruits of *C. zeylanicum* also show antioxidant and radical scavenging activities.³⁶ Gas chromatographic-mass spectrometry studies showed that the main components of the twig essential oil of *C. osmophloeum* Kaneh are *l*-bornyl acetate (15.89%), caryophyllene oxide (12.98%), gamma-eudesmol (8.03%), beta-caryophyllene (6.60%), *T*-cadinol (5.49%), delta-cadinene (4.79%), *trans*-beta-elemene (4.25%), cadalene (4.19%), and *trans*-cinnamaldehyde

Fig. 2 Chemical structures of relevant isolated components of cinnamon.

(4.07%); and *trans*-cinnamaldehyde, caryophyllene oxide, *L*-borneol, *L*-bornyl acetate, eugenol, β -caryophyllene, *E*-nerolidol, cinnamyl acetate, α -terpineol and *p*-allylanisole could inhibit the production of NO by lipopolysaccharide (LPS)-stimulated macrophages, thus exhibiting anti-inflammatory properties.³⁷ (*E*)-Cinnamyl acetate (36.59%) and (*E*)-caryophyllene (22.36%), which possess good antioxidant activity were found to be major compounds in the volatile oil of *C. zeylanicum* fruit stalks that possess good antioxidant capacity.³⁸ Several flavonoids obtained from cinnamon also show DPPH radical scavenging activity.³⁹ The major compounds of the hydrodistilled volatile oil of the *C. zeylanicum* buds are terpene hydrocarbons (78%), alpha-bergamotene (27.38%), alpha-copaene (23.05%) and oxygenated terpenoids (9%).⁴⁰ The chemical composition of the flower oil of *C. zeylanicum* was analysed by GC and GC-MS, and it has been reported that (*E*)-cinnamyl acetate (41.98%), *trans*-alpha-bergamotene (7.97%), and caryophyllene oxide (7.2%) are major compounds.⁴¹ The contents and activities of the chemical constituents of different parts of cinnamon are summarized in Table 1.^{42–44}

3. Side effects and toxicity of cinnamon

Cinnamon is safe to use as a spice and/or flavouring agent. It has been reported that cinnamon has minimal toxic and

adverse effects.⁴⁵ Thirty healthy adults in a clinical trial were instructed to take water extracts of *C. zeylanicum* with the dose increased at monthly intervals (85 mg d⁻¹, 250 mg d⁻¹ and 500 mg d⁻¹).⁴⁶ It has been reported that no serious adverse effects (including hypersensitivity) occurred during the 3-month treatment period or 3-month follow-up period after taking *C. zeylanicum* extract.⁴⁶ An *in vitro* study found that indigenous cinnamon (*C. osmophloeum*) twig extracts had no toxicity on 3T3-L1 preadipocytes at 100 mg mL⁻¹.⁴⁷ Moreover, a plethora of animal and cell experiments have demonstrated that cinnamon and its constituents alleviate the natural toxin-induced and chemical-induced toxicities.^{48–56} In MPTP mouse model of Parkinson's disease, daily treatment with cinnamon powder (100 mg per kg body weight, 7 days) protected striatal tyrosine hydroxylase fibers from the toxicity of MPTP and restored the neurotransmitters level.⁴⁸ In 3 month old Sprague-Dawley male rats, intragastrical pre-treatment with 2.5 ml per kg body weight *Oleum cinnamomi* 1 h before the ethanol administration protected the stomach, liver and kidney from ethanol-induced damage.⁴⁹ In healthy Wistar albino rats, oral administration with aqueous bark extract of *C. zeylanicum* ((2.0 g kg⁻¹, 14 days) showed protective effect against doxorubicin induced cardiotoxicity.⁵⁰ It was reported that cinnamon diet (25 mg mL⁻¹, 10 days) had a marginal protective effect against paraquat in female flies and cinnamon diet (2.5, 25, and 75 mg mL⁻¹, 10 days) could extend lifespan in the fly.⁵¹ In male adult Sprague-Dawley rats, both cinnamic acid (50 mg kg⁻¹, p.o., 7 days) and cinnamaldehyde (40 mg

Table 1 The concentration and activities of chemical constituents in different parts of cinnamon

Parts of cinnamon	Dominant ingredients	Activity	Ref.
Bark	Cinnamaldehyde: 65.00 to 80.00%	Antioxidant, anti-inflammatory, blood vessel protection and hypoglycemic and anti-bacterial effects	27–30 and 42–44
Leaves	Eugenol: 5.00 to 10.00%	Antioxidant activity	42–44
	Eugenol: 70.00 to 95.00%	Antioxidant activity	31 and 42–44
	Cinnamaldehyde: 1.00 to 5.00%	Antioxidant, anti-inflammatory, blood vessel protection and hypoglycemic and anti-bacterial effects	43 and 44
Fruit	<i>Trans</i> -Cinnamyl acetate: 42.00 to 54.00%	—	36 and 42
	Caryophyllene: 9.00 to 14.00%	—	36 and 42
Twigs	<i>l</i> -Bornyl acetate: 15.89%	Anti-inflammatory activity	37
	Caryophyllene oxide: 12.98%	Anti-inflammatory activity	37
	Gamma-eudesmol: 8.03%	—	37
Fruit stalks	Cinnamyl acetate: 36.59%	Antioxidant activity	38
	Caryophyllene: 22.36%	—	38
Buds	Alpha-bergamotene: 27.38%	—	40
	Alpha-copaene: 23.05%	—	40
Flowers	(<i>E</i>)-Cinnamyl acetate: 41.98%	—	41
	<i>Trans</i> -Alpha-bergamotene: 7.97%	—	41
	Caryophyllene oxide: 7.20%	—	41

kg⁻¹, p.o., 7 days) revealed the ameliorative effects on cisplatin-induced splenotoxicity.⁵² In male albino rats, pre-treatment with cinnamon aqueous extract (200 mg per kg per day body weight, 3 times weekly for 50 days) was revealed to ameliorate the Bisphenol A- and octylphenol-induced pathological changes in kidney, brain and testis.⁵³ Another study showed that erythrocytes suspensions incubated with cinnamaldehyde (40 µM) could reduce the hazardous effects of cyadox, maintain the normal function of the body cells and protect the cells against oxidative injury.⁵⁴ In male Wister rats, cinnamon extract (200 mg per kg body weight orally, 8 weeks) was revealed to improve the liver and kidney functions and ameliorate the toxic effect of cadmium.⁵⁵ In cultured human lymphocytes, cinnamic acid (0.74, 3.70, 7.40, 14.8, 74.0, 148 mg ml⁻¹) was shown to possess antigenotoxic effects against H₂O₂ induced genotoxicity.⁵⁶ Despite this, several studies have identified some side effects that cinnamon may cause in clinical practice. A 13-week repeat-dose oral toxicity study on rats revealed that the use of cinnamon extract in excess of the daily recommended dose, 2000 mg kg⁻¹, may increase the weight of the kidney/liver and the total cholesterol (TC) content.⁵⁷ *In vitro* mammalian cell micronucleus assays indicated that cinnamon extract (312.5, 625, 1250 µg ml⁻¹) was not aneugenic or clastogenic, and *in vivo* bone marrow micronucleus assays demonstrated that cinnamon extract (500, 1000, 2000 mg per kg body weight) was not cytotoxic.⁵⁷ A systematic review of cinnamon's adverse effects identified that cinnamon could cause allergic reactions and gastrointestinal disease, which are self-limiting in most cases.⁵⁸ A clinical trial involving 15 patients showed that oral administration of 80 mg ethanol extract of cinnamon twice daily for 4 weeks caused stomach aches, nausea, and constipation.⁵⁹ In a randomized, controlled trial, one of 54 diabetic patients in the cinnamon treatment group developed a rash after administration with usual care with management changes plus 1 g cinnamon capsules daily for 90

days.⁶⁰ We should also be careful when there is repeated exposure to high levels of cinnamaldehyde (100 µM, 20 min) as an *in vitro* study on human induced pluripotent stem cell-derived cardiac myocytes (hiPSC-CMs) revealed that cinnamon may cause progressive electrical remodelling and cardiac dysfunction.⁶¹ In addition, a randomized controlled trial involving 23 females in the cinnamon group found that some females with polycystic ovarian syndrome developed headaches (4), heartburn symptoms (2), menstrual cramps (2), and nausea with diarrhoea (1) after taking 1.5 g of cinnamon powder daily for 6 months.⁶² Moreover, seven of the 20 seasonal allergic rhinitis patients who received 200 µg/200 µL cinnamon nasal spray twice a day for 4 weeks developed headaches, coughs, fevers, body aches, and throat irritation.⁶³ Generally, adverse reactions should be monitored when high doses or long durations of cinnamon are for medical purposes, and further study pertaining to cinnamon's toxicity mechanism is necessary.

4 Cinnamon in the treatment of CVDs

4.1 Atherosclerosis (AS)

AS, which leads to lumen stenosis or obstruction, is a crucial cause of various CVDs.⁶⁴ The occurrence of AS is associated with endothelial dysfunction, elevated blood lipids, imbalanced oxidative stress, dysregulation of the immune response, inflammatory response, growth and mobilization of VSMCs, platelet activity and thrombosis, and angiogenesis.⁶⁵ Cinnamon exhibits protective effects against AS by modulating various proatherogenic cellular events (Fig. 3).

4.1.1. Endothelium protection. AS is a complex disease characterized by arterial intima damage. Endothelial dysfunction, the primary stage of AS, is accompanied by a decrease in

Fig. 3 The anti-atherosclerotic effects by which cinnamon alleviates the development of AS.

endothelial permeability and the expression of cytokines and adhesion molecules; later, lipids and macrophages in the blood tend to deposit in the subendothelial space, which further leads to the formation of foam cells.⁶⁶ Endothelium-dependent diastolic dysfunction is also an important cause of aggravation of atherosclerotic disease. Endothelial cells (ECs) attach to the lining of blood vessels and play a significant role in regulating vascular tension and maintaining the vascular smooth surface whose dysfunction is due to decreased secretion of NO and increased levels of endothelin.⁶⁷ NO is generated by three isozymes of nitric oxide synthase: endothelial nitric oxide synthase (eNOS), the most important transmitter for EC function; neuronal nitric oxide synthase (nNOS); and inducible nitric oxide synthase (iNOS), which is assumed to be a harmful enzyme and a major contributor to AS in pathological conditions.^{68,69} Endogenous NO can adjust vascular tension and inhibit the proliferation of vascular smooth muscle, the aggregation of platelets and the development of inflammation.

In isolated rat aortic rings pre-treated with KCl (60 mM), an aqueous extract of *C. zeylanicum* Blume stem bark exhibited cumulative vasodilating effects partially *via* enhancement of endothelial NO production and activation of KATP channels in VSMCs.⁷⁰ A study in isolated rat thoracic aortae showed that cinnamaldehyde obviously alleviated the exaggerated contraction, improved endothelial NO production and attenuated detrimental advanced glycation end products (AGEs)-inflicted vascular damage.⁷¹ Cinnamaldehyde also exerts endothelium-

dependent vasorelaxant effects, which are affected by NO; and endothelium-independent vasorelaxant effects by blocking Ca^{2+} channels in isolated rat aortae.⁷² Eugenol enhances the expression of eNOS and the accumulation of intracellular calcium, thus protecting human umbilical vein endothelial cells (HUVECs) from oxidized low-density lipoprotein (ox-LDL)-induced dysfunction.⁷³ Furthermore, cinnamaldehyde was demonstrated to preserve NO levels *via* endogenous nuclear factor (erythroid-derived 2)-like 2 protein (Nrf2) activation, thus preserving endothelium-dependent relaxation in the endothelium of mouse aortas treated with high glucose.⁷⁴ According to the experimental results, cinnamon has a beneficial effect on protecting endothelial function through various pathways.

4.1.2. Hypolipidemic effect. Dyslipidaemia is a crucial factor for the occurrence of atherosclerotic CVDs.⁷⁵ Low-density lipoprotein (LDL) and other apolipoprotein (apo) B-containing lipoproteins involving very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and lipoprotein (a) [Lp(a)] are retained and accumulate in the intima of the arterial wall, which together with inflammation and the immune response contribute to the formation of atherosclerotic plaques.^{76,77} Ox-LDL is closely related to the formation of foam cells whose apoptosis and necrosis result in the release of lipids and the development of AS.⁷⁸ It has been reported that plasma high-density lipoprotein (HDL) promotes the outflow of cholesterol, which is inversely associated with the risk of atherosclerotic CVD.⁷⁹ Epidemiological and genetic evi-

dence indicates that elevated triglycerides (TGs) are implicated in the development of CVD.⁸⁰ TG-rich lipoprotein degradation and uptake into macrophage foam cells in the intima of arteries can lead to inflammation in atherosclerotic CVD.⁸¹

A clinical study involving 60 diabetic patients demonstrated that daily consumption of 1, 3, or 6 g of cinnamon reduced low-density lipoprotein cholesterol (LDL-C), mean TG, and TC levels.¹⁵ Multiple clinical trials on cinnamon and its constituents have yielded similar results.^{46,72–74} Ranasinghe *et al.* investigated the efficacy and safety of cinnamon in healthy adults.⁴⁶ Subjects were instructed to take the water extract of *C. zeylanicum* with the dose increased at monthly intervals (85 mg d⁻¹, 250 mg d⁻¹ and 500 mg d⁻¹).⁴⁶ No significant alteration was observed in HDL-L, VLDL-d and TG levels; and a significant decrease in TC and LDL-C was noted after 3 months of treatment.⁴⁶ Azimi *et al.* reported that the consumption of cinnamon (3 g d⁻¹) for 8 weeks reduced TC, LDL, and HDL levels in T2D patients.⁸² A randomized double-blind control trial evaluated the effect of oral cinnamon consumption (2.5 g d⁻¹) on body composition and metabolic parameters in individuals with metabolic syndrome.⁸³ Serum TC, LDL-C, TG, and HDL-L showed significantly greater improvement in the intervention group.⁸³ Askari *et al.* conducted a randomized double-blind placebo-controlled trial on fifty patients with non-alcoholic fatty liver disease (NAFLD).⁸⁴ After 12 weeks of treatment with cinnamon (1.5 g d⁻¹), obvious reductions were observed in TC, TG and LDL-C level.⁸⁴ Paradoxically, a single-blind randomized crossover study demonstrated that there was no difference in the TC, HDL, or LDL levels of 9 healthy adults treated with 3 g cinnamon or wheat flour (placebo).⁸⁵ A clinical trial by Blevins was designed to observe the effects of cinnamon on patients with type 2 diabetes.⁸⁶ The results showed that the lipid levels had no significant change after daily treatment with 1 g cinnamon for 3 months.⁸⁶

Cinnamon and its extract exhibit lipid-lowering effects in animal experiments. Treatment with cinnamic acid reduced TC and LDL-C levels and increased high-density lipoprotein cholesterol (HDL-C) levels in rats.⁸⁷ Moreover, the aqueous extract of *C. zeylanicum* significantly prevented dyslipidaemia and protected aortae from the atherosclerotic changes induced by dexamethasone in Wistar rats.⁸⁸ *S*-(+)-Linalool, a major constituent of the leaf essential oil of *C. osmophloeum* ct. Linalool, and leaf essential oil resulted in significantly decreased blood TG levels and suppressed lipid accumulation by downregulating 3T3-L1 adipocyte differentiation in mice.⁸⁹

The molecular mechanism by which cinnamon and its extracts improve lipid profiles is mainly involved in regulating enzymes or genes related to the generation, accumulation, transport and degradation of lipids. First, cinnamon reduces lipogenesis. A large number of studies have revealed that cinnamon attenuates lipogenic processes in the liver and adipose tissue. The chronic inclusion of aqueous cinnamon extract improves the lipid profile in the liver and adipose tissue by downregulating the mRNA expression of sterol regulatory element-binding protein-1c (SREBP-1c) and the mRNA

expression of sterol regulatory element-binding protein-2 (SREBP-2) and its target genes 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoAR), cholesterol acyltransferase-1 (ACAT-1) and diacylglycerol *O*-acyltransferase 2 (DGAT2), which are directly involved in lipogenesis.⁹⁰ *Trans*-Cinnamic acid plays a positive role in regulating lipid metabolism in a series of adipocyte models. *Trans*-Cinnamic acid was found to reduce the expression of the transcription factors CCAAT/enhancer-binding protein- α (C/EBP- α) and peroxisome proliferator-activated receptor γ (PPAR γ) in white adipocytes, which tightly modulate the conversion of preadipocytes to mature adipocytes; and increase their expression in brown adipocytes.⁹¹ Furthermore, *trans*-cinnamic acid stimulated the adiponectin (ADIPOQ) secretion and AMP-activated protein kinase (AMPK) activation involved in Gi/Go-protein-coupled receptors (GPRs) in differentiated 3T3-L1 cells.⁹² *Trans*-Cinnamic acid can activate β 3-adrenergic receptors (β 3-ARs) and consequently activate protein kinase A (PKA), thus phosphorylating hormone-sensitive lipase (pHSL); and activate AMPK to increase the levels of pHSL and adipocyte triglyceride lipase (ATGL) to upregulate lipid catabolism in 3T3-L1 adipocytes.⁹¹ In C57BL/Ks db/db mice, lower TG and TC contents and higher HDL-C and HTR levels (HDL-C/TC $\times$ 100) were observed after treatment with *Cinnamomi cassiae* (Cinnamon bark) extract due to the enhanced expression of PPAR α in the liver and PPAR γ in adipose tissue.⁹³ Cinnamaldehyde upregulates the expression of HSL and downregulates the expression of glycerol-3-phosphate dehydrogenase (GPD) and adipocyte marker genes, including PPAR- γ and C/EBP- α , to increase adipose tissue lipolysis in mature 3T3-L1 adipocytes *in vitro*.⁹⁴ In the adipose tissue of fructose-fed rats, cinnamon extract enhanced the mRNA levels of ADIPOQ, a protein with anti-atherosclerotic potential; and inhibited the level of CD36, an ox-LDL scavenger receptor associated with an increased risk of AS in patients with type 2 diabetes and insulin resistance.^{95,96}

Cinnamon could also improve the intestinal absorption of fat in food. Microsomal TG transfer protein (MTP) is a microsomal protein that facilitates the conversion of VLDL by catalysing the shift of lipids to nascent apoB-containing lipoprotein particles.⁹⁷ A cinnamon extract (cinnulin PF), high in type A polyphenols, may repress postprandial hyper-triglycerides and the overproduction of apoB48 by inhibiting the overexpression of MTP and SREBP-1c mRNA levels in enterocytes isolated from fructose-fed hamsters.⁹⁸ Another study on the primary enterocytes of chow-fed rats showed that aqueous cinnamon extract suppresses genes associated with elevated levels of cholesterol, triacylglycerols, and apolipoprotein-B48, including adenosine triphosphate-binding cassette subfamily G member 5 (Abcg5), Niemann-Pick c1-like 1 (Npc1l1), CD36, microsomal triacylglycerol transfer protein (Mttp), and SREBP-1c; and facilitates adenosine triphosphate-binding cassette transporter-1 (Abca1) expression.⁹⁹

Second, cinnamon could improve the accumulation of lipids. previous research showed that cinnamon reduces lipid accumulation *via* the upregulation of SREBP-1c, SREBP2, forkhead box O1 (FOXO1) mRNA, and LDL receptors (LDLRs) in

adult male zebrafish.¹⁰⁰ Another possible mechanism by which cinnamon alleviates lipid accumulation is regulating the expression of cholesteryl ester transfer protein (CETP), a plasma protein that accelerates the migration of cholesteryl ester from HDL to LDL particles.¹⁰¹ In high-cholesterol diet (HCD)-fed rabbits, cinnamaldehyde prevents lipid accumulation and decreases the levels of TC, TGs, and LDL-C, which might be related to the lower mRNA expression of CETP.²⁹ In mouse RAW264.7 macrophage cells, two cinnamic acid derivatives, 4-hydroxycinnamic acid (*L*-phenylalanine methyl ester) amide and 3,4-dihydroxyhydrocinnamic acid (*L*-aspartic acid dibenzyl ester) amide, suppress cellular cholesterol storage and transport by inhibiting the allosteric enzymes acyl-CoA: ACAT-1 and ACAT-2 to demonstrate their anti-atherosclerotic potential.¹⁰² Intake of cinnamon polyphenol significantly decreases the lipid profile specifically by suppressing the expression of hepatic SREBP-1c, liver X receptor- α (LXR- α), ATP-citrate lyase (ACLY), and fatty acid synthase (FAS) and enhancing PPAR- α expression in the livers of rats fed a high-fat diet (HFD).¹⁰³ Studies have demonstrated that the modulatory mechanism of the effect of cinnamon on lipid metabolism has multiple pathways, which are expected to offer new ideas and pharmacological bases for the treatment of AS.

4.1.3. Antioxidative effect. Oxidative stress is a state of imbalance between oxidation and antioxidation. During oxidative stress, the production of reactive oxygen species (ROS) exceeds the scavenging capacity of the antioxidant system, leading to the accumulation of ROS and the main pathological state of oxidative stress.¹⁰⁴ Excessive production of ROS promotes lipid peroxidation and the formation of ox-LDL, which then facilitates the secretion of monocyte chemoattractant protein 1 (MCP-1), a protein that can draw monocytes through the EC space to a lesion from ECs. Furthermore, overproduction of ROS can induce EC apoptosis and smooth muscle cell proliferation and migration to promote the development of AS.¹⁰⁵

A double-blind placebo-controlled trial involving twenty-two subjects revealed that administration of 250 mg of an aqueous extract of cinnamon (cinnulin PF) for 12 weeks shows increased ferric reducing antioxidant power and decreased plasma malondialdehyde (MDA) levels.¹⁶ Conversely, a single-blind randomized crossover study of nine healthy young adults showed that the use of 3 g cinnamon supplementation following a high-fat meal had no effect on arterial stiffness and oxidative stress.⁸⁵

Positive results were obtained in *in vivo* and *in vitro* experiments. An *in vitro* study in HUVECs demonstrated that eugenol treatment inhibits reactive ROS generation.⁷³ Experimental data also revealed that new cinnamic acid derivatives possess useful biological activity as anti-atherosclerotic agents with the inhibition of LDL oxidation in mouse RAW264.7 macrophage cells.¹⁰² Furthermore, superoxide dismutase (SOD), glutathione S-transferase (GST), catalase (CAT), glutathione peroxidase (Gpx), haemeoxygenase-1 (HO-1), HMOX1, NAD(P)H dehydrogenase, and quinone 1 (NQO1) are antioxidant enzymes that are conducive to inhibiting the oxidation of LDL. Dietary cinnamate, a phenolic compound

found in cinnamon bark, enhances CAT and Gpx activities and suppresses lipid peroxidation in rats fed a high cholesterol diet.¹⁰⁶ In HFD and streptozotocin (STZ)-induced diabetic rats, eugenol was demonstrated to reduce the level of MDA and increase the serum level of glutathione (GSH). Previous evidence has uncovered that cinnamaldehyde enhances SOD and CAT activities, restores the expression levels of HO-1, and increases aortic NO metabolite (NOx) content in HCD-fed rabbits.²⁹

Molecular mechanism studies showed that cinnamaldehyde reversed intracellular ROS production through the Toll-like receptor 4-NADPH oxidase 4 (TLR4-NOX4) pathway in male Sprague-Dawley rats stimulated by LPS.¹⁰⁷ An experiment using db/db mice showed that cinnamaldehyde attenuated oxidative stress status and increased phosphorylated endothelial nitric oxide synthase (p-eNOS) through activating the Nrf2 signalling pathway.¹⁰⁸ Nrf2 can induce the transcription of antioxidant enzymes such as HO-1, HMOX1 and NQO1 by transferring them from the cytoplasm to the nucleus to regulate the adaptive response of cells to oxidative stress.¹⁰⁹ Cinnamaldehyde elevated the cellular protein level of HO-1 and facilitated the translocation of Nrf2 to the nucleus in HUVECs, which indicated that Nrf2/HO-1 may be the pathway by which cinnamaldehyde protects against oxidative stress.¹⁷ In mouse aortas under high glucose conditions, cinnamaldehyde exerts antioxidant effects mediated through Nrf2 activation and the upregulation of downstream target proteins, including HO-1, NQO1, CAT, and glutathione peroxidase 1 (Gpx-1).⁷⁴ In short, the anti-atherosclerotic effects of cinnamon can also be explained by its antioxidative properties.

4.1.4. Regulation of immune response. Macrophages differentiate from monocytes that migrate under the endothelium engulf ox-LDL to generate foam cells.¹¹⁰ If the foam cells exceed the clearing ability of HDL, a large number of them will die and contribute to the formation of lipid pools and promote the migration of smooth muscle cells in the middle layer of the artery to the intima.¹¹¹ Macrophage scavenger receptors (SRAs) are the main scavenger receptors by which macrophages phagocytose modified LDL. Receptors including CD36 may also be involved in the removal of oxidized LDL particles and the formation of foam cells, and CD11b facilitates monocyte recruitment in atherogenic lesions.¹¹² In phorbol-12-myristate-13-acetate (PMA)-stimulated THP-1 cells, cinnamon water extract interfered with monocyte differentiation and macrophage scavenger activity by decreasing the expression of costimulatory molecules (CD11b and CD36), the uptake of acetyl LDL, and the expression of SRA associated with mitigated activity of extracellular signal-related kinase 1/2 (ERK 1/2).¹¹³ In addition, Kim's research results showed that cinnamaldehyde has also been demonstrated to regulate monocyte/macrophage-mediated immune responses by attenuating the upregulation of surface levels of CD80 and CD69, Toll-like receptor 2 (TLR2) and complement receptor 3 (CR3) while enhancing the levels of adhesion molecules such as CD29 and CD43 to block cell-cell adhesion.¹¹⁴ In addition, cinnamaldehyde could be developed as an immunoregulatory

drug to prevent AS by exhibiting the functional activation of monocytes and macrophages due to the inhibition of phosphoinositide-3-kinase (PI3K) and phosphoinositide-dependent kinase 1 (PDK1) and nuclear factor- κ B (NF- κ B) activation.¹¹⁴ These research data reveal that regulation of the immune response is also a pivotal part of the mechanism of cinnamon in the treatment of AS.

4.1.5. Anti-inflammatory activity. Atherogenesis is a chronic inflammatory reaction.¹¹⁵ Leukocyte recruitment and proinflammatory cytokines play crucial roles in the early stages of atherogenesis. Activation of the inflammatory cascades in vascular ECs stimulates the biosynthesis of adhesion molecules (vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selection) and chemokines (MCP-1) and promotes the recruitment and retention of circulating monocytes in the intima membrane, which then differentiate into macrophages and aggravate atherosclerotic lesions by transforming into foam cells and secreting plentiful proinflammatory factors.^{116,117}

A clinical trial has demonstrated the anti-inflammatory effects of cinnamon. In a randomized double-blind clinical trial involving 36 women with rheumatoid arthritis, the levels of serum inflammatory factors in the cinnamon group and the control group treated with placebo for 8 weeks were compared. Serum CRP and tumour necrosis factor- α (TNF- α) levels in the cinnamon group were significantly lower than those in the placebo group.¹¹⁸ However, a clinical trial studied 44 adult patients with type 2 diabetes who received either three grams cinnamon supplementation or placebo. The results elucidated that ingestion of cinnamon did not reduce the plasma levels of NF- κ B, sirtuin-1 (SIRT1), hs-CRP, interleukin (IL)-6 and TNF- α in type 2 diabetes patients.¹¹⁹ Furthermore, there was no significant difference in the serum levels of ICAM-1 and VCAM-1 in patients between the groups.¹²⁰

In addition, many *in vitro* experiments have identified the anti-inflammatory effects of cinnamon. The production of adhesion molecules and subsequent attachment of leukocytes to ECs are the key early events in the pathological process of atherogenesis. Liao's research showed that CA and *C. cassia* extracts inhibited the expression of VCAM-1 and ICAM-1 and the TNF-induced adhesion of monocytes to ECs at the transcriptional level in human ECs.¹²¹ A study using endotoxin-injected mice showed that cinnamaldehyde and linalool mitigated the endotoxin-induced levels of interleukin-1 β (IL-1 β), IL-18, TNF- α , interferon (IFN)- γ , and inflammatory mediator high-mobility group box 1 protein (HMGB-1) in the spleen and mesenteric lymph nodes.¹²² In THP-1 monocytes, *trans*-cinnamaldehyde and *p*-cymene were found to decrease the secretion of IL-8 and inhibit the phosphorylation of Akt and inhibitor of NF- κ B (I κ B α).¹²³ Furthermore, Pannetier *et al.* reported that the essential oil of *C. cassia* leaves and cinnamaldehyde reduced the levels of MCP-1, macrophage inflammatory protein-1 α (MIP-1 α), TNF- α , IL-1 β and IL-6 and inhibited the expression of cyclooxygenase-2 (COX-2) and microsomal prostaglandin-E synthase-1 (mPGES-1) in LPS-activated J774A.1 cells.¹²⁴ Cassia leaf oil and cinnamaldehyde enhanced mRNA expression and

the generation of the anti-inflammatory mediators IL-10 and transforming growth factor- β (TGF- β) in LPS-activated J774A.1 cells.¹²⁴

In addition, extensive experimental work has clarified the molecular and cellular pathways of inflammation through which cinnamon promotes AS. Tristetraprolin (TTP) family proteins have anti-inflammatory effects, and cinnamon polyphenol extract was found to enhance TTP and TNF mRNA levels in mouse RAW264.7 macrophages.¹²⁵ A plethora of molecular mechanism studies have demonstrated that cinnamon extract can reduce inflammation by modulating NF- κ B, which has been regarded as the central mediator of the inflammatory process.¹²⁶ NO produced by iNOS plays a crucial role in the pathogenesis of various inflammatory diseases. Experimental data revealed that 2'-hydroxycinnamaldehyde isolated from *C. cassia* Blume bark inhibits NF- κ B activation, thus hindering NO production in RAW264.7 cells.¹²⁷ Moreover, cinnamaldehyde significantly lowered the levels of TNF- α , and prostaglandin E2 (PGE2) inhibited the expression of iNOS, COX-2, NF- κ B, and I κ B α in LPS-stimulated mouse macrophages (RAW264.7).¹²⁸ Cinnamaldehyde was elucidated to significantly reduce the overproduction of inflammatory cytokines, decrease the expression of matrix metalloproteinase-2 (MMP-2) and achieve an anti-atherosclerotic effect through the I κ B α /NF- κ B signalling pathway in an HFD-fed ApoE^{-/-} atherosclerotic mouse model.¹²⁹ In TNF α -treated ECs, cinnamaldehyde inhibits p65 nuclear translocation and ICAM-1 expression by mediating the activity of NF- κ B and glutaredoxin-1 (Grx-1).¹³⁰ In a study using endotoxin-induced mice, cinnamaldehyde and linalool, two major active components in the essential oil of *C. osmophloeum* leaves, inhibited the activation of NF- κ B and caspase-1 activity by decreasing the expression of toll-like receptor 4/myeloid differentiation protein 2 (TLR4/MD2), myeloid differentiation primary response gene 88 (MyD88), nod-like receptor family, pyrin domain containing 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC), and caspase-1 in the spleen and mesenteric lymph nodes to exhibit an anti-inflammatory effect.¹²² Cinnamaldehyde elevates the expression of the Nrf2-related gene HO-1, which is associated with the suppressed expression of TNF α -induced ICAM-1, over long-term pre-treatment to elicit anti-inflammatory activity in TNF α -treated ECs.¹²¹ Hong's study showed that treatment with cinnamon water extract reduced serum LPS-induced TNF- α by blocking the degradation of I κ B α and the activation of c-Jun NH2-terminal kinase (JNK), p38, and ERK 1/2 *in vivo*.¹³¹ In conclusion, these studies demonstrated that cinnamon extracts may be promising drugs for the treatment and prevention of the inflammatory response in atherogenesis.

4.1.6. Suppression of VSMC growth and mobilization. Pharmacological effects with antiproliferative and antimigratory properties on VSMCs are conducive to treating AS, given that unlimited proliferation and movement of VSMCs within the arterial wall contribute to plaque expansion and vascular narrowing.¹³² Cinnamaldehyde was shown to repress the proliferation and migration of VSMCs and decrease the prolifera-

tive index of injured arteries in Zucker diabetic fatty rats.¹³³ Another *in vitro* study also indicated that cinnamaldehyde inhibited ox-LDL-induced VSMC proliferation and migration in VSMCs.¹³⁴ Platelet-derived growth factor (PDGF) is a potent mitogen and chemoattractant that has been found to promote the proliferation and migration of VSMCs.¹³⁵ Previous research reported that cinnamon extracts, including cinnamyl alcohol, cinnamic acid, and eugenol, inhibit PDGF-BB-triggered VSMC proliferation by arresting the cell cycle at G0/G1 phase; down-regulating the expression of cell cycle-positive regulatory proteins by upregulating p21 and p27 expression; and inhibiting the phosphorylation of anti-phospho-phospholipase C- γ 1 (PLC γ 1), anti-phospho-phosphatidylinositol 3-kinase-linked protein kinase B (AKT), p38, and JNK, which regulate the activation of VSMC proliferation.^{136–138} Previous research reported that 2-methoxycinnamaldehyde, a natural compound of *C. cassia*, suppresses PDGF-induced migration of human aortic smooth muscle cells (HASMCs) and inhibits TNF- α -induced proliferation of HASMCs by lowering the cyclin D1, cyclin D3, cyclin-dependent kinase 4 (CDK 4) and CDK6 levels and enhancing the levels of cyclin-dependent kinase inhibitors p21 and p27.¹³⁹ Thus, the therapeutic utility of cinnamon in AS has been partly attributed to suppression of VSMC growth and mobilization.

4.1.7. Repression of platelet activity and thrombosis.

Because of circulating haemorheologic abnormalities or pro-coagulant material upregulation in atherosclerotic lesion areas, platelets are extensively activated and recruited to the damaged endothelium, which initiates the coagulation cascade, thereby inducing a life-threatening acute coronary event, artery thrombosis and vascular occlusion.¹⁴⁰ An experiment using a rat model revealed that administration of cinnamaldehyde significantly prolonged haemorrhage and coagulation times by mitigating platelet aggregation and thrombosis.¹⁴¹ *In vitro* and in endotoxin-treated normal rats, methanolic extract from Cinnamomi Cortex and cinnamic aldehyde, major essential oily components of methanolic extract, repressed the platelet aggregation triggered by collagen, arachidonic acid and adenosine diphosphate.¹⁴² Eugenol, amygdalactone, 2-methoxycinnamaldehyde, and coniferaldehyde, 4 compounds obtained from *C. cassia*, elicited inhibitory potencies on arachidonic acid-, U46619 (a thromboxane A₂ mimic), and epinephrine-induced platelet aggregation in an *in vitro* study.¹⁴³ Thromboxane A₂ (TAX2) is the main cyclo-oxygenase derivative of arachidonic acid in platelets and an effective platelet aggregation agent. Cinnamophilin in cinnamon was found to be a TAX2 receptor antagonist that inhibited platelet aggregation in human platelet-rich plasma and rat aortae.¹⁴⁴ According to the findings, it is evident that repression of platelet activity and thrombosis is a crucial constituent of the atheroprotective effects of cinnamon.

4.1.8. Inhibition of angiogenesis. Angiogenesis can aggravate inflammatory responses, induce haemorrhages in the plaque, affect the stability of the plaque, and consequently lead to the occurrence of acute cardiovascular events.^{145,146} A water extract of *C. cassia* represses vascular endothelial growth

factor (VEGF)-induced angiogenesis in HUVECs by suppressing the tyrosine phosphorylation of VEGFR2 and induces a decrease in VEGF-stimulated microvessel outgrowth in an *ex vivo* angiogenesis model of a rat aortic ring.¹⁴⁷ In HUVECs treated with phorbol ester, cinnamon extract was observed to repress protein kinase C (PKC α and PKC η) mRNA and PKC-dependent phosphorylation of MAPK (pMAPK) in a dose-dependent manner and suppress the mRNA expression of vascular endothelial growth factor receptor 1 (VEGFR1/Flt1) and vascular endothelial growth factor receptor 2 (VEGFR2/KDR/Flk1) to exert inhibitory effects on angiogenesis.¹⁴⁸ Experimental data indicate the potential of cinnamon extracts as a good therapeutic drug for inhibiting angiogenesis to improve AS.¹⁴⁹

4.2. Hypertension

Hypertension is a common CVD whose continuous progression may lead to a variety of heart, brain, kidney and other complications. Previous research identified that short-term administration of cinnamon shows promising BP lowering potential.¹⁵⁰ In a randomized, placebo-controlled clinical trial, Ziegenfuss *et al.* showed that the cinnamon group (0.5 g d⁻¹, 12 weeks) had significant decreases in FBG and systolic blood pressure (SBP), small but statistically significant decreases in body fat and an increase in lean mass, suggesting that cinnamon was effective in lowering BP.¹⁵¹ Another clinical study yielded similar results.¹⁵² Akilen *et al.* reported that cinnamon (2 g d⁻¹) for 12 weeks lowered glycated haemoglobin (HbA1C), SBP and diastolic blood pressure (DBP) in poorly controlled type 2 diabetes patients.¹⁵² A randomized, placebo-controlled clinical trial was designed to evaluate the hypotensive effect of cinnamon. Subjects with type 2 diabetes were instructed to take cinnamon (2.4 g d⁻¹) at the first treatment period visit.¹⁵³ At the second treatment visit, volunteers were instructed to reduce their intake of cinnamon to 1.2 g d⁻¹ as a maintenance dose.¹⁵³ After a 12-week treatment period, Wainstein *et al.* observed lower blood pressures than the baseline values. However, the by-treatment difference in SBP was a function of a regression to the mean rather than a change related to treatment.¹⁵³ Consistent with this, consumption of a water extract of *C. zeylanicum* was reported to significantly reduce SBP and DBP in healthy adults.⁴⁶ A single supplement with cinnamon (3 g d⁻¹, 16 weeks) was revealed to significantly improve the BP of individuals with metabolic syndrome in a randomized double-blind control trial.⁸³ In a randomized double-blind clinical trial, DBP was significantly lower after the administration of cinnamon powder (500 mg d⁻¹, 8 weeks) in women with rheumatoid arthritis.¹¹⁸ A meta-analysis showed that cinnamon may play a hypotensive role in adults.¹⁵⁴

The intake of cinnamon lowered the SBP of spontaneously hypertensive rats consuming sucrose-containing diets. Several studies have shown that cinnamon exerts hypotensive effects through various mechanisms, such as improving endothelial dysfunction, regulating ion channels, and suppressing oxidative stress.¹⁵⁵ The production of NO has a protective effect on the endothelium.⁶⁶ Cinnamaldehyde was demonstrated to

improve the relaxation of methylglyoxal (MG)-injured aortas, enhance NO production from isolated aortae, and repress AGE prompted by MG to ameliorate exaggerated vasoconstriction.⁷¹ The methanol extract of *C. zeylanicum* stem bark possesses antihypertensive effects due to the ability to elevate the production of endogenous NO in L-arginine analogues such as N^ω-nitro-L-arginine methyl-ester (L-NAME)-induced hypertensive rats.¹⁵⁶ Another animal experiment revealed that the acute intravenous injection of *C. zeylanicum* Blume stem bark aqueous extract could decrease the mean arterial BP in a rat model partially by increasing endothelial NO.⁷⁰ Micelles containing cinnamaldehyde could also induce endothelium-dependent and NOS-dependent relaxations of coronary vascular smooth muscle mediated by NO and H₂O₂.¹⁵⁷ Phosphorylated eNOS at serine 1177 (eNOS-Ser1177) plays a key role in producing NO from ECs. Upregulation of eNOS upstream kinases, such as AMPK, AKT, or PKA, promotes eNOS phosphorylation and may improve endothelial dysfunction. *Trans*-Cinnamaldehyde stimulates HUVECs to promote the release of NO by significantly increasing eNOS and AKT phosphorylation and its upstream target PI3K, insulin receptor substrate 1 (IRS1).¹⁵⁸ Angiotensin converting enzyme (ACE), a nonspecific enzyme in vascular ECs, promotes the conversion of angiotensin I to angiotensin II, which then contracts arteries and veins to increase BP. Cinnamic acid is endowed with a strong effect on the regulation of BP by suppressing ACE activity in serum and defending animals against vasoconstriction in HFD-induced obese rats.¹⁵⁹ The function of KATP channels is reduced in hypertension models.¹⁶⁰ *C. zeylanicum* Blume stem bark aqueous extract could activate KATP channels in vascular smooth muscle and reduce BP.¹⁵⁶ An increased intracellular concentration of Ca²⁺ would lead to higher vascular wall tension and consequently elevated BP. Cinnamaldehyde has peripheral vasodilatation properties by blocking Ca²⁺ channels in mouse ventricular cardiomyocytes and in mesenteric artery smooth muscle cells.¹⁶¹ In isolated rings of porcine coronary arteries, cinnamaldehyde could relax the coronary arteries by inhibiting the sensitivity of Ca²⁺ and influx of Ca²⁺ endothelium-independently.¹⁵⁷

Activation of the transient receptor potential ankyrin 1 (TRPA1) channel can cause peripheral vasodilation and a biphasic blood pressure response.¹⁶² Intravenously injected TRPA1 agonist cinnamaldehyde contributed to a transient hypotensive response and decreased heart rate (HR) dose-dependently, followed by a more sustained pressor response depending on dose.¹⁶³ The BP response was lower in TRPA1 KO mice treated with cinnamaldehyde, which showed the involvement of TRPA1 in the modulation of BP.¹⁶³ Oxidative stress has been implicated in vascular stiffness and remodelling, which is a crucial process of hypertension.¹⁶⁴ Cinnamaldehyde was demonstrated to regulate oxidative stress. In rats with fructose-induced hypertension, cinnamaldehyde decreased the elevated SBP and DBP; restored the levels of antioxidants such as Gpx, CAT, SOD, and GSH; and lowered MDA levels.¹⁶⁵ These experiments suggested the great potential of cinnamon in treating hypertension.

4.3. Myocardial ischaemia-reperfusion injury (MIRI)

Acute myocardial infarction (AMI) is a leading cause of morbidity and mortality worldwide.¹⁶⁶ After treatment for acute myocardial infarction, the coronary artery will be reperfused. However, the process of reperfusion can result in cardiomyocyte death, which is known as myocardial ischaemia reperfusion injury.¹⁶⁷ Cinnamon and its extracts have been found to reduce infarct size and bring benefits to the treatment of myocardial infarction through various mechanisms. Administration of *C. zeylanicum* bark extract significantly improved ischaemia/reperfusion (I/R)-induced myocardial injury by reducing the infarct size and exhibited a significant decrease in serum cardiac troponin I (cTnI), lactate dehydrogenase (LDH), and MDA levels in a rat model of regional heart ischaemia.¹⁶⁸ 2-Methoxycinnamaldehyde (2-MCA), an active ingredient of *C. cassia*, could obviously improve I/R-injury myocardial dysfunction and reduce infarct size in adult male rats.¹⁶⁹ The underlying mechanism is that 2-MCA exhibits its antioxidant and anti-inflammatory action through decreasing the expression of HMGB1 and VCAM-1 in I/R myocardium along with increasing HO-1 induction and enhancing SOD activity in ischaemic tissues.¹⁶⁹ Cinnamaldehyde is a TRPA1 agonist, and TRPA1 was found to drive myofibroblast trans-differentiation initiated after MI injury, which is important to maintain ventricular wall integrity and to reduce dilation after infarction remodelling.¹⁷⁰ Thus, TRPA1 may be a possible target for cinnamon to treat MIRI.

4.4. Viral myocarditis

Viral myocarditis is a disease of inflammatory destruction of the myocardium after myocardial virus infection and is a common cause of sudden cardiac death and dilated cardiomyopathy.¹⁷¹ Research has shown that cinnamon may have the potential to treat viral myocarditis. Previous research demonstrated that α -bromo-4-chlorocinnamaldehyde, synthesized by cinnamaldehyde, dose-dependently decreased the viral titers and alleviated cardiac pathological changes in a coxsackie virus B3-induced viral myocarditis model.¹⁷³ The underlying mechanism might be inhibiting inflammatory signalling as BCC inhibits the secretion of inflammatory cytokines such as TNF- α , IL- β and IL-6 in cardiomyocytes; suppresses the activation of NF- κ B and the degradation and phosphorylation of I κ B α ; and reduces the protein level of TLR4 in hearts.¹⁷²

4.5. Heart failure

Myocardial fibrosis accelerates the development of heart dysfunction and eventually leads to heart failure.¹⁷³ Cinnamaldehyde was identified to improve cardiac fibrosis, which exhibited possible benefits for the treatment of heart failure.¹⁷⁴ Cinnamaldehyde was revealed to inhibit NLRP3 inflammasome activation by blocking CD36-mediated TLR4/6-IL-1R-associated kinase 4/1 (IRAK4/1) signalling to protect rats from fructose-induced cardiac inflammation and fibrosis.¹⁷⁴

4.6. Arrhythmias

There are few studies on the effect of cinnamon on arrhythmias, which needs further study. The only study we retrieved demonstrated that myocardial ischaemia rats after oral administration of *C. zeylanicum* bark extract showed reduced ventricular tachycardia and ventricular ectopic beat episodes, smoother ST segment changes, shorter QTc, lower R-wave amplitude, and increased heart rate during ischaemia compared to the control group.¹⁶⁸

5. Cinnamon in the treatment of diabetes

Diabetes mellitus (DM) is closely related to CVD, which is the most common cause of morbidity and mortality in diabetic patients.¹⁷⁵ DM has been shown to independently exacerbate the initiation and progression of AS and blunt the regression of lesions following lipid lowering.¹⁷⁶ DM is characterized by chronic hyperglycaemia due to insufficient insulin secretion and/or insulin dysfunction.¹⁷⁷ Long-term metabolic disorder of carbohydrates, fat and protein will result in damage to the eyes, kidneys, nerves, heart, blood vessels and other tissues and organs. Furthermore, it was estimated that diabetes prevalence, deaths and health care expenditures attributable to diabetes would cause a large burden on society, finance and the health system worldwide.¹⁷⁸ Cinnamon and its extracts have been demonstrated to have therapeutic effects on diabetes mellitus and its cardiovascular complications. The effects of cinnamon on improving diabetes may be achieved in a variety of ways.^{179–185}

5.1. Enhancement of insulin sensitivity and insulin secretion

Multiple studies have reported that cinnamon and its extracts possess the capacity to enhance insulin sensitivity and insulin secretion.¹⁸⁶ Administration of *C. cassia* and *zeylanicum* extracts was found to increase plasma insulin in rats.¹⁸⁷ Polyphenols from cinnamon restored pancreatic weight and alleviated mesenteric white fat accumulation related to improved insulin sensitivity in high fat/high fructose (HF/HF)-fed rats.¹⁸⁸ Polyphenols from cinnamon have been shown to improve insulin sensitivity in HF/HF-fed rats.¹⁸⁸ The influence of cinnamon on insulin sensitivity and its secretion is achieved by a variety of signalling pathways. Insulin-like growth factor 1 (IGF-1), produced by the liver, could promote glucose uptake in peripheral tissues, increase insulin sensitivity, and inhibit the release of glucose in the liver.^{189,190} Previous research reported that encapsulated cinnamon oil emulsion (COE) improved the concentrations of glucose, insulin and amylase and enhanced IGF-1 mRNA expression in diabetic rats.¹⁹¹ Insulin receptor- β (IR- β) is auto-phosphorylated and plays a role in phosphorylating insulin receptor substrates. HPLC-purified cinnamon polyphenols increased the levels of IR- β in 3T3-L1 adipocytes.¹⁹² NO was found to promote the uptake of insulin-mediated glucose in muscle and play an important

role in peripheral tissue uptake of glucose.^{193,194} The pathway involving IR- β , IRS1, PI3K and eNOS has been reported to account for important physiological actions of insulin in facilitating the production of NO.^{195,196} In HFD-fed rats, cinnamon extract prevented insulin resistance, enhanced the tyrosine phosphorylation levels of IR- β and IRS-1, and strengthened the association between IRS1 and PI3K by improving NO production.¹⁹⁷ Additionally, the decreased AKT signalling is closely related to hepatic insulin resistance.¹⁹⁸ Previous research reported that cinnamaldehyde upregulates the IRS1/PI3K/AKT2 signalling pathway to induce its hypoglycaemic effect in a STZ-induced T2D rat model.¹⁹⁹ Cinnamaldehyde was revealed to induce the activation of PPAR δ , PPAR γ and retinoid X receptor (RXR) to enhance insulin sensitivity.²⁰⁰ *In vivo* and *in vitro* studies have identified that cinnamic acid dose-dependently improved glucose tolerance and obviously enhanced insulin secretion in isolated islets.²⁰¹ Cinnamon extracts suppressed the expression of glycogen synthase kinase 3 beta (GSK3B), insulin-like growth factor receptor (IGF1R), IGF2R, and phosphatidylinositol 3-kinase regulatory subunit 1 (PIK3R1), which encodes insulin signalling pathway proteins in adipocytes that exhibit antidiabetic activity.²⁰² It is well known that protein tyrosine phosphatase 1B (PTP1B) alleviates the signalling pathways of insulin and leptin receptors. Indigenous cinnamon (*C. osmophloeum*) twig extracts were found to inhibit PTP1B activity and exhibit great potential as natural health products.⁴⁷ ADIPOQ is known to improve insulin resistance. In 3T3-L1 adipocytes, treatment with *trans*-cinnamic acid increased the level of ADIPOQ, which is involved in stimulated GPRs.²⁰³ In 3T3-L1 adipocytes, cinnamaldehyde was revealed to improve insulin sensitivity, possibly by activating the TRPA1 pathway.²⁰⁴

5.2. Regulation of the enzyme activity involved in glucose

The regulation of enzyme activities related to glucose metabolism by natural products has attracted much attention.²⁰⁵ In db/db mice, cinnamon extract was revealed to decrease the activity of small intestinal α -glycosidase, which converts carbohydrates into glucose and slows the absorption of carbohydrates in the small intestine.²⁰⁶ Cumulative findings have produced similar results.²⁰⁷ Cinnamon bark extracts were found to inhibit intestinal α -glucosidase and pancreatic α -amylase and exhibited potential in reducing postprandial glucose.²⁰⁸ Another *in vitro* study revealed that cinnamon may inhibit lipase, α -amylase and α -glucosidase digestive enzymes.²⁰⁹ In rat hepatoma cells, aqueous cinnamon extract was also found to decrease the gene expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), which regulate hepatic gluconeogenesis, to reduce FBG.²¹⁰

5.3. Regulation of glucose metabolism in liver, adipose tissue and muscle

The liver plays an important role in glucose metabolism by converting glucose into liver glycogen for storage. Cinnamon extract could increase liver glycogen content, improve insulin

action in liver tissues, reduce liver fat and improve glucose homeostasis.²¹¹ The upregulation of glucose transporter 2 (GLUT2) expression may increase the hepatic glucose output to the circulatory system.²¹² SREBP-1c increases the level of GLUT2 mRNA in a primary hepatocyte model.²¹³ Increased FAS mRNA expression is associated with restricted conversion of glucose into fatty acids. PEPCK mRNA is a limiting gene in gluconeogenesis.²¹⁴ COE dose-dependently decreased hepatic GLUT2, FAS, SREBP-1c and PEPCK gene expression in diabetic rats.¹⁹¹ GLUT-1 could facilitate the transport of glucose into cells.²¹⁵ Cinnamon extract was reported to upregulate the expression of GLUT1 mRNA levels in adipocytes.²⁰² Reduced activity of pyruvate kinase (PK) in the liver tissue of diabetic rats is associated with reduced glycolysis and amplified gluconeogenesis. Cinnamaldehyde was found to enhance PK levels and alleviate PEPCK levels in diabetic rats.²¹⁶

Glucose can be converted into fat stored in adipose tissue or converted into muscle glycogen in muscle. Cinnamon was revealed to facilitate the uptake of glucose in adipose tissue and muscle. GLUT4, the main transporter for glucose removal from the circulatory system, works after insulin stimulation. Uncoupling protein-1 (UCP-1) promotes the uptake of glucose by brown adipose tissue. An aqueous cinnamon extract upregulated UCP-1 and GLUT4 in brown adipose tissues and muscles of STZ-induced diabetic rats.²¹⁷ Serum levels of retinol binding protein 4 (RBP4) and the expression of RBP4 were increased in IR mice, and serum RBP4 levels were negatively correlated with the expression of adipose tissue glucose transporter 4 (GLUT4).^{218,219} Previous research reported that cinnamaldehyde displays outstanding antidiabetic efficacy by decreasing serum RBP4 levels and enhancing the expression of tissue GLUT4 protein.²²⁰ In 3T3 adipocytes, treatment with a cinnamon extract increased glucose uptake but inhibited the secretion of the antidiabetic hormone ADIPOQ to levels that were nondetectable.²²¹ In C57BLKS db/db mice, cinnamaldehyde upregulated the mRNA expression of GLUT-4 and the protein expression of p-Akt in skeletal muscle, which suggested that cinnamaldehyde could regulate the stimulation and translocation of GLUT4 to exert antidiabetic effects.²²² In 3T3-L1 adipocytes and C2C12 myotubes, cinnamon extract stimulated the LKB1-AMPK signalling cascade, consequently leading to increased glucose uptake.²²³

5.4. Protection of islet cells

Cinnamon polyphenols have been shown to ameliorate the pathological damage of pancreatic beta cells in STZ-diabetic mice.¹⁷⁵ In addition, cinnamon methanol extract ameliorated pancreatic functions and restored them to a normal state due to the antioxidant activity acquired by their phenolic phytochemicals in diabetic rats.²²⁴ Oxidative stress and the inflammatory response may lead to islet β cell injury.^{225,226} Attenuating oxidative stress and anti-inflammation are crucial ways for cinnamon to treat diabetes. Previous research demonstrated that camphor could enhanced the activity of Gpx, CAT, SOD, and the GSH content in the pancreatic tissues of alloxan-induced diabetic rats.²²⁷ Consistent with this is that STZ-

induced diabetic rats treated with *C. tamala* leaf oil experienced reduced blood glucose levels and increased plasma insulin levels, which may be attributed to the antioxidant effect of *C. tamala* leaf oil.²²⁸ COE improved the histological picture of the liver and pancreas by enhancing antioxidant capacity.¹⁹¹ Trimer procyanidin oligomers in cinnamon extracts protected pancreatic β -cells by increasing cell viability and reducing ROS accumulation in H₂O₂-treated β -cells.²²⁹ Previous research demonstrated that premating treatment with cinnamaldehyde alleviated the levels of leptin, TNF- α , MDA and NO while enhancing the levels of GSH and CAT activity at term pregnancy in fatty-sucroed diet/STZ (FSD/STZ)-induced gestational diabetic rats.²³⁰ Leaf essential oil from indigenous cinnamon was reported to enhance the activities of SOD and GSH and ameliorate pancreatic levels of IL-1 β , TNF- α and NO, thus protecting pancreatic β cells.²³¹ Human islet amyloid polypeptide (hIAPP), a 37 residue peptide hormone, aggregates and causes dysfunction of pancreatic β -cells.^{232,233} Proanthocyanidins in cinnamon water extract repressed the amyloid formation of hIAPP and obviously improved the membrane damaging and cytotoxic effects due to hIAPP aggregation.²³⁴ Moreover, cinnamon oil was demonstrated to promote the immunoreactivity of pancreatic islet β -cells in type 2 diabetic mice.²³⁵

5.5. Modulating gut microbiota

Several animal experiments have identified that PTPBs could reduce blood glucose by altering the composition of the gut microbiota. Previous research reported that treatment with polyphenol-containing extracts from cinnamon bark significantly improved the insulin resistance index in mice fed a HFD, which was achieved by modulating the microbiota composition and reducing inflammation.²³⁶ Cinnamaldehyde intervention was demonstrated to significantly increase *Lactobacillus johnsonii* in T1DM mice, suggesting that cinnamaldehyde could protect against STZ-induced T1DM by interfering with gut microbiota.²³⁷

5.6. Improvement of diabetes complications

Cinnamon also shows prospects for improving diabetic complications. AGEs are a stable and heterogeneous group of compounds that are involved in the pathogenesis of diabetic complications.²³⁸ *C. burmanii*, *Vietnamese*; *C. loureirii* and *Ceylon*; *C. zeylanicum* showed great potential to suppress the formation of AGEs.²³⁹ In diabetic rats, cinnamon and its active component procyanidin-B2 (PCB2) inhibited AGE accumulation and ameliorated AGE-mediated pathogenesis of diabetic nephropathy.²⁴⁰ It has also been reported that the procyanidin-B2 fraction has the physiological significance of delaying diabetic cataracts by repressing AGEs in diabetic rats.²⁴¹ Cinnamic aldehyde was reported to ameliorate common metabolic disorder symptoms related to diabetes, improve renal function and minimize pathological alterations by activating Nrf2.²⁴² Moreover, multiple substances, including nonpolar sesquiterpenoids, in the bark of *C. cassia* were reported to exhibit renoprotective effects by suppressing the expression of

fibronectin, MCP-1 and IL-6 in high glucose-induced mesangial cells, which provided evidence for clinical applications of cinnamon in diabetic nephropathy prevention and treatment.²⁴³ Consistent with this, administration of cinnamon oil was revealed to blunt oxidant stress-induced renal injury in alloxan-induced diabetic rats due to its antioxidant and insulin interaction properties.²⁴⁴ Furthermore, cinnamaldehyde treatment prevents the elevation of BP in insulin deficiency and insulin resistance by normalizing vascular contractility in rats.²⁴⁵ Cinnamaldehyde was also revealed to improve behavioural deficits in diabetic rats by enhancing brain ChE activity and neurotransmitter levels and reducing IL-6 and TNF- α levels.²⁴⁶ Administration of cinnamic acid was revealed to significantly improve dose-dependent memory in STZ-induced diabetic mice by alleviating oxidative stress and cholinergic dysfunction.²⁴⁷ In obese/T2D female mice, cinnamaldehyde has been shown to possess potential therapeutic value for the management of diabetic gastroparesis, which may be related to modulating key regulating detoxifying enzymes by Nrf2-mediated gastric estrogen receptors (ERs) and nNOS function.²⁴⁸ In addition, the topical application of cinnamon increased fibroblast proliferation and glucose uptake in keratinocytes and consequently accelerated wound healing during diabetes by enhancing the antioxidant capacity and the expression of cyclin D1, GLUT-1 and IGF-1.²⁴⁹

6. Clinical trials of cinnamon and its extracts in DM

Multiple clinical trials revealed that cinnamon improved glycaemic indicators [fasting plasma glucose (FPG), two-hour postprandial glucose (2hpp), HbA1c, fasting insulin, and insulin resistance] and clarified the hypoglycaemic properties of cinnamon. Khan *et al.* conducted a randomized, placebo-controlled study on 60 subjects with T2DM.¹⁵ After 40 days of treatment with cinnamon (1, 3, or 6 g d⁻¹), an improvement was observed in the mean fasting serum glucose levels (18–29%).¹⁵ A triple-blind placebo-controlled randomized clinical trial was conducted in patients with T2DM to investigate the efficacy of cinnamon.²⁵⁰ After consuming 500 mg capsules of cinnamon bark twice daily for 3 months, subjects exhibited improved glycaemic indices including FPG, 2hpp, HbA1c, fasting insulin, and insulin resistance.²⁵⁰ Crawford compared the effects of cinnamon capsules (1 g d⁻¹) plus usual care with management changes or usual care with management changes for 90 days in type 2 diabetes patients.⁶⁰ After the treatment period, the cinnamon group showed lower HbA1c than the usual care alone group.⁶⁰ Similarly, Mang *et al.* showed that aqueous cinnamon extract (3 g d⁻¹) reduced fasting plasma glucose levels.²⁵¹ The effects were more obvious in subjects with a higher initial plasma glucose level, which showed the potential of cinnamon for treating diabetic patients with poor glycaemic control.²⁵¹ Lu *et al.* reported that cinnamon extract (120 and 360 mg d⁻¹) decreased HbA1c and FBG levels in a randomized, double-blinded clinical study.²⁵²

A randomized, placebo-controlled, triple-blind clinical trial was designed to evaluate the effects of cinnamon (3 g d⁻¹) for 90 days in people with type 2 diabetes.²⁵³ The cinnamon group exhibited statistically significant reductions in HbA1c and fasting venous glucose compared with the placebo group.²⁵³ Consistent with this, supplementation with cinnamon decreased the HOMA index and FBG in patients with NAFLD.⁸⁴ Despite this, studies have demonstrated that cinnamon does not contribute to glycaemic control and has no preventive or ameliorating effect on metabolic diseases.²⁵⁴ Altschuler *et al.* conducted a prospective, double-blind, placebo-controlled study on 72 adolescent type 1 diabetic subjects.²⁵⁵ After 90 days of treatment with cinnamon (1 g d⁻¹), no significant differences were observed in the final A1C, change in A1C, total daily insulin intake, or number of hypoglycaemic episodes.²⁵⁵ A double-blind, randomized, placebo-controlled clinical trial evaluated the hypoglycaemic effects of cinnamon (3 g d⁻¹, 8 weeks) in patients with T2DM.²⁵⁶ No significant changes were observed in the levels of FBG, insulin, haemoglobin bA1c, or HOMA-IR between the cinnamon supplementation group and the placebo group.²⁵⁶

7. Conclusion and future perspectives

In conclusion, a large amount of literature has shown that cinnamon and its components possess great potential in treating diabetes and CVDs, including AS, hypertension, MIRI, viral myocarditis, heart failure, and arrhythmias (Fig. 4 and 5). The potential of cinnamon has been tested in a number of clinical trials, animal and cell experiments (ESI Tables 1 and 2†). Generally, cinnamon's therapeutic capacity for CVDs is attrib-

Fig. 4 Molecular mechanism underlying cinnamon protects against hypertension, MIRI, viral myocarditis, heart failure and arrhythmias.

Fig. 5 Molecular mechanism of cinnamon on diabetes.

ted to its multifactorial functions. Cinnamon and its extracts, especially cinnamaldehyde, increase the production of endothelial NO by activating the Nrf2 signalling pathway and enhancing pAKT-Ser473 and eNOS-Ser1177, thereby protecting ECs. Cinnamon and its extracts, in particular cinnamaldehyde and *trans*-cinnamic acid, might attenuate lipogenic processes, improve the intestinal absorption of fat in food and lower the accumulation of lipids to regulate lipid metabolism, thus reducing the risk of CVD. In addition, cinnamon and its extracts could blunt the production of ROS and ameliorate the level of antioxidant enzymes to mitigate the formation of ox-LDL, thereby preventing the occurrence of AS. Cinnamaldehyde can regulate oxidative stress in a TLR4-NOX4- and Nrf2-dependent manner. Furthermore, cinnamon and its extracts have strong roles in modulating immune responses and inflammatory responses. Moreover, cinnamon extracts, such as cinnamaldehyde, cinnamyl alcohol, cinnamic acid, and eugenol, can suppress the growth and mobilization of VSMCs by regulating the cell cycle. Cinnamon and its extracts also repress platelet activity and thrombosis and inhibit angiogenesis, which are helpful in protecting against CVDs.

The impact of cinnamon on diabetes is ambiguous. Some clinical studies have yielded conflicting results on whether cinnamon improves glucose metabolism. Several mechanisms

could be responsible for the supposed positive effects of cinnamon on diabetes, including enhancing insulin sensitivity and insulin secretion; regulating the enzyme activity involved in glucose; regulating glucose metabolism in the liver, adipose tissue and muscle; ameliorating oxidative stress and inflammation to protect islet cells; and improving diabetes complications.

Evidence for cinnamon and its extracts as a natural product to prevent and counteract CVDs and diabetes is increasing.²⁵⁷ Nevertheless, most experiments were conducted in animals and *in vitro*, and the clinical effect and metabolic impact in humans need to be further determined. Concluding that intake of cinnamon or its extracts is a useful way to ameliorate the pathological process of CVDs and diabetes is probably premature. Long-term, large-sample, randomized and controlled trials are required to clarify the role of cinnamon in the control of CVDs and diabetes.

Abbreviations

2-MCA	2-Methoxycinnamaldehyde
HMG-CoAR	3-Hydroxy-3-methylglutaryl-CoA reductase
AMI	Acute myocardial infarction

Abcg5	Adenosine triphosphate-binding cassette sub-family G member	HFD	High-fat diet
Abca1	Adenosine triphosphate-binding cassette transporter-1	HMGB-1	High-mobility group box 1 protein
ATGL	Adipocyte triglyceride lipase	HOMA-IR	Homeostatic model assessment for insulin resistance
ADIPOQ	Adiponectin	HASMCs	Human aortic smooth muscle cells
AGEs	Advanced glycation end products	hiPSC-CMs	Human induced pluripotent stem cell-derived cardiac myocytes
AMPK	AMP-activated protein kinase	hiAPP	human islet amyloid polypeptide
ACE	Angiotensin converting enzyme	HUVECs	Human umbilical vein endothelial cells
AKT	Anti-phospho-phosphatidylinositol 3-kinase-linked protein kinase B	IRAK4/1	IL-1R-associated kinase 4/1
PLC γ 1	Anti-phospho-phospholipase C- γ 1	iNOS	Inducible nitric oxide synthase
ASC	Apoptosis-associated speck-like protein containing a caspase-recruitment domain	I κ B α	Inhibitor of NF- κ B
AS	Atherosclerosis	IRS1	Insulin receptor substrate 1
ACLY	ATP-citrate lyase	IR- β	Insulin receptor- β
cTnI	Cardiac troponin I	IGF-1	Insulin-like growth factor 1
CVDs	Cardiovascular diseases	IGF1R	Insulin-like growth factor 1 receptor
CAT	Catalase	ICAM-1	Intercellular adhesion molecule-1
C/EBP- α	CCAAT/enhancer-binding protein-alpha	IFN- γ	Interferon- γ
ACAT-1	Cholesterol acyltransferase-1	IL-1 β	Interleukin-1 β
CETP	Cholesteryl ester transfer protein	IDL	Intermediate-density lipoprotein
C.	Cinnamomum	I/R	Ischaemia/reperfusion
JNK	c-Jun NH2-terminal kinase	LDH	Lactate dehydrogenase
CR3	Complement receptor 3	LDLRs	LDL receptors
CDK 4	Cyclin-dependent kinase 4	LPS	Lipopolysaccharide
COX-2	Cyclooxygenase-2	[Lp(a)]	Lipoprotein (a)
DM	Diabetes mellitus	LXR- α	Liver X receptor- α
DGAT2	Diacylglycerol O-acyltransferase 2	LDL	Low-density lipoprotein
DBP	Diastolic blood pressure	LDL-C	Low-density lipoprotein cholesterol
COE	Encapsulated cinnamon oil emulsion	MIP-1 α	Macrophage inflammatory protein-1 α
ECs	Endothelial cells	MMP-2	Matrix metalloproteinase-2
eNOS	Endothelial nitric oxide synthase	MG	Methylglyoxal
ERs	Estrogen receptors	mPGES-1	Microsomal prostaglandin-E synthase-1
ERK 1/2	Extracellular signal-related kinase 1/2	MTP	Microsomal TG transfer protein
FBG	Fasting blood glucose	Mttp	Microsomal triacylglycerol transfer protein
FPG	Fasting plasma glucose	MCP-1	Monocyte chemotactic protein 1
FAS	Fatty acid synthase	MyD88	Myeloid differentiation primary response gene 88
FSD/STZ	Fatty-sucrosed diet/STZ	MIRI	Myocardial ischaemia-reperfusion Injury
FOXO1	Forkhead box O1	NQO1	NAD(P)H dehydrogenase, and quinone 1
GPRs	Gi/Go-protein-coupled receptors	nNOS	Neuronal nitric oxide synthase
GLUT2	Glucose transporter 2	Npc1l1	Niemann-Pick c1-like 1
GLUT4	Glucose transporter 4	NO	Nitric oxide
G6Pase	Glucose-6-phosphatase	NOx	NO metabolite
Grx-1	Glutaredoxin-1	NLRP3	Nod-like receptor family, pyrin domain containing 3
Gpx	Glutathione peroxidase	Nrf2	Nuclear factor (erythroid-derived 2)-like 2 protein
Gpx-1	Glutathione peroxidase 1	NF- κ B	Nuclear factor- κ B
GST	Glutathione S-transferase	L-NAME	N ω nitro-L-arginine methyl-ester
HbA1C	Glycated haemoglobin	ox-LDL	Oxidized low-density lipoprotein
GPD	Glycerol-3-phosphate dehydrogenase	PPAR γ	Peroxisome proliferator-activated receptor γ
GSK3B	Glycogen synthase kinase 3 beta	PMA	Phorbol-12-myristate-13-acetate
HO-1	Haemeoxygenase-1	PIK3R1	Phosphatidylinositol 3-kinase regulatory subunit 1
HR	Heart rate	PEPCK	Phosphoenolpyruvate carboxykinase
HF/HF	High fat/high fructose	PI3K	Phosphoinositide-3-kinase
HDL	High-density lipoprotein	PDK1	Phosphoinositide-dependent kinase 1
HDL-C	High-density lipoprotein cholesterol

p-eNOS	Phosphorylated endothelial nitric oxide synthase
pHSL	Phosphorylating hormonesensitive lipase
pMAPK	Phosphorylation of MAPK
PDGF	Platelet-derived growth factor
PCB2	Procyanidin-B2
PGE2	Prostaglandin E2
PKA	Protein kinase A
PKC	Protein kinase C
PTP1B	Protein tyrosine phosphatase 1B
PK	Pyruvate kinase
ROS	Reactive oxygen species
RXR	Retinoid X receptor
RBP4	Retinol binding protein 4
SRAs	Scavenger receptors
SIRT1	Sirtuin-1
SREBP 1c	Sterol regulatory element-binding protein 1c
SREBP 2	Sterol regulatory element-binding protein 2
STZ	Streptozotocin
SOD	Superoxide dismutase
SBP	Systolic blood pressure
ESCOP	The german commission E and the european scientific cooperative on phytotherapy
TAX2	Thromboxane A2
TLR2	Toll-like receptor 2
TLR4/MD2	Toll-like receptor 4/myeloid differentiation protein 2
TLR4-	Toll-like receptor 4-NADPH oxidase 4
NOX4	
TC	Total cholesterol
TGF- β	Transforming growth factor- β
TRPA1	Transient receptor potential ankyrin 1
TGs	Triglycerides
TTP	Tristetraprolin
TNF- α	Tumour necrosis factor- α
2hpp	Two-hour postprandial glucose
UCP-1	Uncoupling protein-1
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor
VEGFR	Vascular endothelial growth factor receptor
VSMC	Vascular smooth muscle cell
VLDL	Very low-density lipoprotein
β 3-ARs	β 3-adrenergic receptors

Author contributions

CS, HC-L and XQ-F wrote the main text. HC-L and XQ-F contributed equally to this work. CS, HC-L, XQ-F, YL-W, ZL-J, YQ, MX, ZH-S and LY-X reviewed the literature available; JL-G, YD-L and XN-C revised the manuscript.

Conflicts of interest

The authors declare that they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

Acknowledgements

This work was funded by grants from the National Natural Science Foundation of China (No. 81973842). We thank J. L. Gao, Y. D. Lu, and X. N. Cui for the guidance and revision of this manuscript.

References

- 1 Y. Zheng, S. H. Ley and F. B. Hu, Global aetiology and epidemiology of type 2 diabetes mellitus and its complications, *Nat. Rev. Endocrinol.*, 2018, **14**, 88–98.
- 2 G. A. Mensah, G. A. Roth and V. Fuster, The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond, *J. Am. Coll. Cardiol.*, 2019, **74**, 2529–2532.
- 3 G. A. Roth, C. Johnson, A. Abajobir, F. Abd-Allah, S. F. Abera, G. Abyu, M. Ahmed, B. Aksut, T. Alam, K. Alam, F. Alla, N. Alvis-Guzman, S. Amrock, H. Ansari, J. Arnlov, H. Asayesh, T. M. Atey, L. Avila-Burgos, A. Awasthi, A. Banerjee, A. Barac, T. Barnighausen, L. Barregard, N. Bedi, E. Belay Ketema, D. Bennett, G. Berhe, Z. Bhutta, S. Bitew, J. Carapetis, J. J. Carrero, D. C. Malta, C. A. Castaneda-Orjuela, J. Castillo-Rivas, F. Catala-Lopez, J. Y. Choi, H. Christensen, M. Cirillo, L. Cooper Jr., M. Criqui, D. Cundiff, A. Damasceno, L. Dandona, R. Dandona, K. Davletov, S. Dharmaratne, P. Dorairaj, M. Dubey, R. Ehrenkranz, M. El Sayed Zaki, E. J. A. Faraon, A. Esteghamati, T. Farid, M. Farvid, V. Feigin, E. L. Ding, G. Fowkes, T. Gebrehiwot, R. Gillum, A. Gold, P. Gona, R. Gupta, T. D. Habtewold, N. Hafezi-Nejad, T. Hailu, G. B. Hailu, G. Hankey, H. Y. Hassen, K. H. Abate, R. Havmoeller, S. I. Hay, M. Horino, P. J. Hotez, K. Jacobsen, S. James, M. Javanbakht, P. Jeemon, D. John, J. Jonas, Y. Kalkonde, C. Karimkhani, A. Kasaeian, Y. Khader, A. Khan, Y. H. Khang, S. Khera, A. T. Khoja, J. Khubchandani, D. Kim, D. Kolte, S. Kosen, K. J. Krohn, G. A. Kumar, G. F. Kwan, D. K. Lal, A. Larsson, S. Linn, A. Lopez, P. A. Lotufo, H. M. A. El Razek, R. Malekzadeh, M. Mazidi, T. Meier, K. G. Meles, G. Mensah, A. Meretoja, H. Mezgebe, T. Miller, E. Mirzakhimov, S. Mohammed, A. E. Moran, K. I. Musa, J. Narula, B. Neal, F. Ngalesoni, G. Nguyen, C. M. Obermeyer, M. Owolabi, G. Patton, J. Pedro, D. Qato, M. Qorbani, K. Rahimi, R. K. Rai, S. Rawaf, A. Ribeiro, S. Safiri, J. A. Salomon, I. Santos, M. Santric Milicevic, B. Sartorius, A. Schutte, S. Sepanlou, M. A. Shaikh, M. J. Shin, M. Shishehbor, H. Shore, D. A. S. Silva, E. Sobngwi, S. Stranges, S. Swaminathan, R. Tabares-Seisdedos, N. Tadele Atnafu, F. Tesfay, J. S. Thakur, A. Thrift, R. Topor-Madry, T. Truelsen, S. Tyrovolas, K. N. Ukwaja, O. Uthman, T. Vasankari, V. Vlassov, S. E. Vollset, T. Wakayo, D. Watkins, R. Weintraub, A. Werdecker, R. Westerman, C. S. Wiysonge, C. Wolfe, A. Workicho, G. Xu, Y. Yano, P. Yip, N. Yonemoto, M. Younis, C. Yu, T. Vos, M. Naghavi

- and C. Murray, Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015, *J. Am. Coll. Cardiol.*, 2017, **70**, 1–25.
- 4 A. T. Larkin, C. Hoffman, A. Stevens, A. Douglas and Z. Bloomgarden, Determinants of adherence to diabetes treatment, *J. Diabetes*, 2015, **7**, 864–871.
 - 5 F. Rodriguez, D. J. Maron, J. W. Knowles, S. S. Virani, S. Lin and P. A. Heidenreich, Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease, *JAMA Cardiol.*, 2019, **4**, 206–213.
 - 6 P. P. Hao, F. Jiang, Y. G. Chen, J. Yang, K. Zhang, M. X. Zhang, C. Zhang, Y. X. Zhao and Y. Zhang, Traditional Chinese medication for cardiovascular disease, *Nat. Rev. Cardiol.*, 2015, **12**, 318.
 - 7 X. L. Tong, L. Dong, L. Chen and Z. Zhen, Treatment of diabetes using traditional Chinese medicine: past, present and future, *Am. J. Chin. Med.*, 2012, **40**, 877–886.
 - 8 J. H. O'Keefe, N. M. Gheewala and J. O. O'Keefe, Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health, *J. Am. Coll. Cardiol.*, 2008, **51**, 249–255.
 - 9 S. Deyno, K. Eneyew, S. Seyfe, N. Tuyiringire, E. L. Peter, R. A. Muluye, C. U. Tolo and P. E. Ogwang, Efficacy and safety of cinnamon in type 2 diabetes mellitus and pre-diabetes patients: A meta-analysis and meta-regression, *Diabetes Res. Clin. Pract.*, 2019, **156**, 107815.
 - 10 P. Ranasinghe, R. Jayawardana, P. Galappaththy, G. R. Constantine, N. de Vas Gunawardana and P. Katulanda, Efficacy and safety of 'true' cinnamon (*Cinnamomum zeylanicum*) as a pharmaceutical agent in diabetes: a systematic review and meta-analysis, *Diabetic Med.*, 2012, **29**, 1480–1492.
 - 11 H. Mollazadeh and H. Hosseinzadeh, Cinnamon effects on metabolic syndrome: a review based on its mechanisms, *Iran. J. Basic Med. Sci.*, 2016, **19**, 1258–1270.
 - 12 G. K. Jayaprakash and L. J. Rao, Chemistry, biogenesis, and biological activities of *Cinnamomum zeylanicum*, *Crit. Rev. Food Sci. Nutr.*, 2011, **51**, 547–562.
 - 13 S. F. Nabavi, A. Di Lorenzo, M. Izadi, E. Sobarzo-Sanchez, M. Daglia and S. M. Nabavi, Antibacterial Effects of Cinnamon: From Farm to Food, Cosmetic and Pharmaceutical Industries, *Nutrients*, 2015, **7**, 7729–7748.
 - 14 S. C. Ho, K. S. Chang and P. W. Chang, Inhibition of neuroinflammation by cinnamon and its main components, *Food Chem.*, 2013, **138**, 2275–2282.
 - 15 A. Khan, M. Safdar, M. M. Ali Khan, K. N. Khattak and R. A. Anderson, Cinnamon improves glucose and lipids of people with type 2 diabetes, *Diabetes Care*, 2003, **26**, 3215–3218.
 - 16 A. M. Roussel, I. Hininger, R. Benaraba, T. N. Ziegenfuss and R. A. Anderson, Antioxidant effects of a cinnamon extract in people with impaired fasting glucose that are overweight or obese, *J. Am. Coll. Nutr.*, 2009, **28**, 16–21.
 - 17 N. Y. Kim, N. T. Trinh, S. G. Ahn and S. A. Kim, Cinnamaldehyde protects against oxidative stress and inhibits the TNF α induced inflammatory response in human umbilical vein endothelial cells, *Int. J. Mol. Med.*, 2020, **46**, 449–457.
 - 18 H. K. Kwon, W. K. Jeon, J. S. Hwang, C. G. Lee, J. S. So, J. A. Park, B. S. Ko and S. H. Im, Cinnamon extract suppresses tumor progression by modulating angiogenesis and the effector function of CD8 $^{+}$ T cells, *Cancer Lett.*, 2009, **278**, 174–182.
 - 19 J. Gruenewald, J. Freder and N. Armbruster, Cinnamon and health, *Crit. Rev. Food Sci. Nutr.*, 2010, **50**, 822–834.
 - 20 D. G. Barceloux, Cinnamon (*Cinnamomum* species), *Dis. Mon.*, 2009, **55**, 327–335.
 - 21 B. A. Behbahani, F. Falah, F. L. Arab, M. Vasiee and F. T. Yazdi, Chemical Composition and Antioxidant, Antimicrobial, and Antiproliferative Activities of *Cinnamomum zeylanicum* Bark Essential Oil, *Evidence-Based Complementary Altern. Med.*, 2020, **2020**, 5190603.
 - 22 S. Sultana, F. A. Ripa and K. Hamid, Comparative antioxidant activity study of some commonly used spices in Bangladesh, *Pak. J. Biol. Sci.*, 2010, **13**, 340–343.
 - 23 I. Kallel, B. Hadrich, B. Gargouri, A. Chaabane, S. Lassoued, R. Gdoura, A. Bayoudh and E. B. Messaoud, Optimization of Cinnamon (*Cinnamomum zeylanicum* Blume) Essential Oil Extraction: Evaluation of Antioxidant and Antiproliferative Effects, *Evidence-Based Complementary Altern. Med.*, 2019, **2019**, 6498347.
 - 24 C. H. Yang, R. X. Li and L. Y. Chuang, Antioxidant activity of various parts of *Cinnamomum cassia* extracted with different extraction methods, *Molecules*, 2012, **17**, 7294–7304.
 - 25 Z. Hussain, J. A. Khan, A. Arshad, P. Asif, H. Rashid and M. I. Arshad, Protective effects of *Cinnamomum zeylanicum* L. (Darchini) in acetaminophen-induced oxidative stress, hepatotoxicity and nephrotoxicity in mouse model, *Biomed. Pharmacother.*, 2019, **109**, 2285–2292.
 - 26 G. Singh, S. Maurya, M. P. DeLampasona and C. A. Catalan, A comparison of chemical, antioxidant and antimicrobial studies of cinnamon leaf and bark volatile oils, oleoresins and their constituents, *Food Chem. Toxicol.*, 2007, **45**, 1650–1661.
 - 27 S. Mateen, M. T. Rehman, S. Shahzad, S. S. Naeem, A. F. Faizy, A. Q. Khan, M. S. Khan, F. M. Husain and S. Moin, Anti-oxidant and anti-inflammatory effects of cinnamaldehyde and eugenol on mononuclear cells of rheumatoid arthritis patients, *Eur. J. Pharmacol.*, 2019, **852**, 14–24.
 - 28 M. Friedman, Chemistry, Antimicrobial Mechanisms, and Antibiotic Activities of Cinnamaldehyde against Pathogenic Bacteria in Animal Feeds and Human Foods, *J. Agric. Food Chem.*, 2017, **65**, 10406–10423.
 - 29 O. A. A. Nour, G. S. G. Shehatou, M. A. Rahim, M. S. El-Awady and G. M. Suddek, Cinnamaldehyde exerts vasculoprotective effects in hypercholesterolemic rabbits, *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 2018, **391**, 1203–1219.
 - 30 R. Zhu, H. Liu, C. Liu, L. Wang, R. Ma, B. Chen, L. Li, J. Niu, M. Fu, D. Zhang and S. Gao, Cinnamaldehyde in

- diabetes: A review of pharmacology, pharmacokinetics and safety, *Pharmacol. Res.*, 2017, **122**, 78–89.
- 31 S. Chericoni, J. M. Prieto, P. Iacopini, P. Cioni and I. Morelli, In vitro activity of the essential oil of *Cinnamomum zeylanicum* and eugenol in peroxynitrite-induced oxidative processes, *J. Agric. Food Chem.*, 2005, **53**, 4762–4765.
 - 32 F. L. Hsu, W. H. Li, C. W. Yu, Y. C. Hsieh, Y. F. Yang, J. T. Liu, J. Shih, Y. J. Chu, P. L. Yen, S. T. Chang and V. H. Liao, In vivo antioxidant activities of essential oils and their constituents from leaves of the Taiwanese *Cinnamomum osmophloeum*, *J. Agric. Food Chem.*, 2012, **60**, 3092–3097.
 - 33 A. A. Doyle and J. C. Stephens, A review of cinnamaldehyde and its derivatives as antibacterial agents, *Fitoterapia*, 2019, **139**, 104405.
 - 34 B. J. Chen, C. S. Fu, G. H. Li, X. N. Wang, H. X. Lou, D. M. Ren and T. Shen, Cinnamaldehyde Analogues as Potential Therapeutic Agents, *Mini-Rev. Med. Chem.*, 2017, **17**, 33–43.
 - 35 Y. T. Tung, P. L. Yen, C. Y. Lin and S. T. Chang, Anti-inflammatory activities of essential oils and their constituents from different provenances of indigenous cinnamon (*Cinnamomum osmophloeum*) leaves, *Pharm. Biol.*, 2010, **48**, 1130–1136.
 - 36 G. K. Jayaprakasha, M. Ohnishi-Kameyama, H. Ono, M. Yoshida and L. J. Rao, Phenolic constituents in the fruits of *Cinnamomum zeylanicum* and their antioxidant activity, *J. Agric. Food Chem.*, 2006, **54**, 1672–1679.
 - 37 Y. T. Tung, M. T. Chua, S. Y. Wang and S. T. Chang, Anti-inflammation activities of essential oil and its constituents from indigenous cinnamon (*Cinnamomum osmophloeum*) twigs, *Bioresour. Technol.*, 2008, **99**, 3908–3913.
 - 38 G. K. Jayaprakasha, L. J. M. Rao and K. K. Sakariah, Volatile constituents from *Cinnamomum zeylanicum* fruit stalks and their antioxidant activities, *J. Agric. Food Chem.*, 2003, **51**, 4344–4348.
 - 39 M. Okawa, J. Kinjo, T. Nohara and M. Ono, DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants, *Biol. Pharm. Bull.*, 2001, **24**, 1202–1205.
 - 40 G. K. Jayaprakasha, L. J. Rao and K. K. Sakariah, Chemical composition of volatile oil from *Cinnamomum zeylanicum* buds, *Z. Naturforsch., C: J. Biosci.*, 2002, **57**, 990–993.
 - 41 G. K. Jayaprakasha, L. J. M. Rao and K. K. Sakariah, Chemical composition of the flower oil of *Cinnamomum zeylanicum* blume, *J. Agric. Food Chem.*, 2000, **48**, 4294–4295.
 - 42 P. V. Rao and S. H. Gan, Cinnamon: a multifaceted medicinal plant, *Evidence-Based Complementary Altern. Med.*, 2014, **2014**, 642942.
 - 43 N. Singh, A. S. Rao, A. Nandal, S. Kumar, S. S. Yadav, S. A. Ganaie and B. Narasimhan, Phytochemical and pharmacological review of *Cinnamomum verum* J. Presl-a versatile spice used in food and nutrition, *Food Chem.*, 2021, **338**, 127773.
 - 44 Z. Hussain, J. A. Khan and H. Rashid, *Cinnamomum zeylanicum* (Darchini): A Boon to Medical Science and a Possible Therapy for Stress-Induced Ailments, *Crit. Rev. Eukaryot. Gene Expr.*, 2019, **29**, 263–276.
 - 45 P. Ranasinghe, S. Pigera, G. A. Premakumara, P. Galappaththy, G. R. Constantine and P. Katulanda, Medicinal properties of 'true' cinnamon (*Cinnamomum zeylanicum*): a systematic review, *BMC Complementary Altern. Med.*, 2013, **13**, 275.
 - 46 P. Ranasinghe, R. Jayawardena, S. Pigera, W. S. Wathurapatha, H. D. Weeratunga, G. A. S. Premakumara, P. Katulanda, G. R. Constantine and P. Galappaththy, Evaluation of pharmacodynamic properties and safety of *Cinnamomum zeylanicum* (Ceylon cinnamon) in healthy adults: a phase I clinical trial, *BMC Complementary Altern. Med.*, 2017, **17**, 550.
 - 47 G. M. Lin, Y. H. Chen, P. L. Yen and S. T. Chang, Antihyperglycemic and antioxidant activities of twig extract from *Cinnamomum osmophloeum*, *J. Tradit. Complementary Med.*, 2016, **6**, 281–288.
 - 48 S. Khasnavis and K. Pahan, Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease, *J. Neuroimmune Pharmacol.*, 2014, **9**, 569–581.
 - 49 C. Ozbayer, H. Kurt, Z. Ozdemir, T. Tuncel, S. M. Saadat, D. Burukoglu, H. Senturk, I. Degirmenci and H. V. Gunes, Gastroprotective, cytoprotective and antioxidant effects of *Oleum cinnamomi* on ethanol induced damage, *Cytotechnology*, 2014, **66**, 431–441.
 - 50 J. A. N. Sandamali, R. P. Hewawasam, K. Jayatilaka and L. K. B. Mudduwa, *Cinnamomum zeylanicum* Blume (Ceylon cinnamon) bark extract attenuates doxorubicin induced cardiotoxicity in Wistar rats, *Saudi Pharm. J.*, 2021, **29**, 820–832.
 - 51 S. E. Schriner, S. Kuramada, T. E. Lopez, S. Truong, A. Pham and M. Jafari, Extension of *Drosophila* lifespan by cinnamon through a sex-specific dependence on the insulin receptor substrate chico, *Exp. Gerontol.*, 2014, **60**, 220–230.
 - 52 O. M. Abd El-Raouf, E. M. El-Sayed and M. F. Manie, Cinnamic Acid and Cinnamaldehyde Ameliorate Cisplatin-Induced Splenotoxicity in Rats, *J. Biochem. Mol. Toxicol.*, 2015, **29**, 426–431.
 - 53 A. M. Morgan, S. S. El-Ballal, B. E. El-Bialy and N. B. El-Borai, Studies on the potential protective effect of cinnamon against bisphenol A- and octylphenol-induced oxidative stress in male albino rats, *Toxicol. Rep.*, 2014, **1**, 92–101.
 - 54 M. R. Farag, M. Alagawany and V. Tufarelli, In vitro antioxidant activities of resveratrol, cinnamaldehyde and their synergistic effect against cyadox-induced cytotoxicity in rabbit erythrocytes, *Drug Chem. Toxicol.*, 2017, **40**, 196–205.

- 55 A. Ghonim, A. Abdeen, R. El-Shawarby, N. Abdel-Aleem, E. El-Shewy, M. Abdo and E. Abdelhiee, Protective effect of cinnamon against cadmium-induced hepatorenal oxidative damage in rats, *Int. J. Pharmacol. Toxicol.*, 2017, **5**, 17–22.
- 56 G. Taner, D. O. Vardar, S. Aydin, Z. Aytac, A. Basaran and N. Basaran, Use of in vitro assays to assess the potential cytotoxic, genotoxic and antigenotoxic effects of vanillic and cinnamic acid, *Drug Chem. Toxicol.*, 2017, **40**, 183–190.
- 57 J. W. Yun, J. R. You, Y. S. Kim, S. H. Kim, E. Y. Cho, J. H. Yoon, E. Kwon, J. J. Jang, J. S. Park, H. C. Kim, J. H. Che and B. C. Kang, In vitro and in vivo safety studies of cinnamon extract (*Cinnamomum cassia*) on general and genetic toxicology, *Regul. Toxicol. Pharmacol.*, 2018, **95**, 115–123.
- 58 M. Hajimonfarednejad, M. Ostovar, M. J. Raei, M. H. Hashempur, J. G. Mayer and M. Heydari, Cinnamon: A systematic review of adverse events, *Clin. Nutr.*, 2019, **38**, 594–602.
- 59 Y. Nir, I. Potasman, E. Stermer, M. Tabak and I. Neeman, Controlled trial of the effect of cinnamon extract on *Helicobacter pylori*, *Helicobacter*, 2000, **5**, 94–97.
- 60 P. Crawford, Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial, *J. Am. Board Fam. Med.*, 2009, **22**, 507–512.
- 61 M. A. Nystoriak, P. J. Kilfoil, P. K. Lorkiewicz, B. Ramesh, P. J. Kuehl, J. McDonald, A. Bhatnagar and D. J. Conklin, Comparative effects of parent and heated cinnamaldehyde on the function of human iPSC-derived cardiac myocytes, *Toxicol. in Vitro*, 2019, **61**, 104648.
- 62 D. H. Kort and R. A. Lobo, Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome: a randomized controlled trial, *Am. J. Obstet. Gynecol.*, 2014, **211**, 487.
- 63 S. Walanj, A. Walanj, V. Mohan and P. A. Thakurdesai, Efficacy and safety of the topical use of intranasal cinnamon bark extract in seasonal allergic rhinitis patients: A double-blind placebo-controlled pilot study, *J. Herb. Med.*, 2014, **4**, 37–47.
- 64 P. Libby, J. E. Buring, L. Badimon, G. K. Hansson, J. Deanfield, M. S. Bittencourt, L. Tokgozoglu and E. F. Lewis, Atherosclerosis, *Nat. Rev. Dis. Primers*, 2019, **5**, 56.
- 65 H. Lu and A. Daugherty, Atherosclerosis, *Arterioscler., Thromb., Vasc. Biol.*, 2015, **35**, 485–491.
- 66 J. Davignon and P. Ganz, Role of endothelial dysfunction in atherosclerosis, *Circulation*, 2004, **109**, III27–III32.
- 67 D. A. Chistiakov, V. V. Revin, I. A. Sobenin, A. N. Orekhov and Y. V. Bobryshev, Vascular endothelium: functioning in norm, changes in atherosclerosis and current dietary approaches to improve endothelial function, *Mini-Rev. Med. Chem.*, 2015, **15**, 338–350.
- 68 W. K. Alderton, C. E. Cooper and R. G. Knowles, Nitric oxide synthases: structure, function and inhibition, *Biochem. J.*, 2001, **357**, 593–615.
- 69 M. Lind, A. Hayes, M. Caprnda, D. Petrovic, L. Rodrigo, P. Kruzliak and A. Zulli, Inducible nitric oxide synthase: Good or bad?, *Biomed. Pharmacother.*, 2017, **93**, 370–375.
- 70 P. Nyadjeu, A. Dongmo, T. B. Nguelefack and A. Kamanyi, Antihypertensive and vasorelaxant effects of *Cinnamomum zeylanicum* stem bark aqueous extract in rats, *J. Complementary Integr. Med.*, 2011, **8**, 2.
- 71 M. M. Tarkhan, K. S. Balamsh and H. M. El-Bassossy, Cinnamaldehyde protects from methylglyoxal-induced vascular damage: Effect on nitric oxide and advanced glycation end products, *J. Food Biochem.*, 2019, **43**, e12907.
- 72 A. Yanaga, H. Goto, T. Nakagawa, H. Hikami, N. Shibahara and Y. Shimada, Cinnamaldehyde induces endothelium-dependent and -independent vasorelaxant action on isolated rat aorta, *Biol. Pharm. Bull.*, 2006, **29**, 2415–2418.
- 73 H. C. Ou, F. P. Chou, T. M. Lin, C. H. Yang and W. H. Sheu, Protective effects of eugenol against oxidized LDL-induced cytotoxicity and adhesion molecule expression in endothelial cells, *Food Chem. Toxicol.*, 2006, **44**, 1485–1495.
- 74 F. Wang, C. Pu, P. Zhou, P. Wang, D. Liang, Q. Wang, Y. Hu, B. Li and X. Hao, Cinnamaldehyde prevents endothelial dysfunction induced by high glucose by activating Nrf2, *Cell. Physiol. Biochem.*, 2015, **36**, 315–324.
- 75 D. J. Rader and A. Daugherty, Translating molecular discoveries into new therapies for atherosclerosis, *Nature*, 2008, **451**, 904–913.
- 76 K. Skalen, M. Gustafsson, E. K. Rydberg, L. M. Hulten, O. Wiklund, T. L. Innerarity and J. Boren, Subendothelial retention of atherogenic lipoproteins in early atherosclerosis, *Nature*, 2002, **417**, 750–754.
- 77 J. R. Burnett, A. J. Hooper and R. A. Hegele, Lipids and cardiovascular disease, *Pathology*, 2019, **51**, 129–130.
- 78 E. M. Maguire, S. W. A. Pearce and Q. Xiao, Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease, *Vasc. Pharmacol.*, 2019, **112**, 54–71.
- 79 J. E. Feig, B. Hewing, J. D. Smith, S. L. Hazen and E. A. Fisher, High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies, *Circ. Res.*, 2014, **114**, 205–213.
- 80 B. G. Nordestgaard and A. Varbo, Triglycerides and cardiovascular disease, *Lancet*, 2014, **384**, 626–635.
- 81 B. G. Nordestgaard, Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology, *Circ. Res.*, 2016, **118**, 547–563.
- 82 P. Azimi, R. Ghiasvand, A. Feizi, M. Hariri and B. Abbasi, Effects of Cinnamon, Cardamom, Saffron, and Ginger Consumption on Markers of Glycemic Control, Lipid Profile, Oxidative Stress, and Inflammation in Type 2 Diabetes Patients, *Rev. Diabet. Stud.*, 2014, **11**, 258–266.
- 83 S. G. Jain, S. Puri, A. Misra, S. Gulati and K. Mani, Effect of oral cinnamon intervention on metabolic profile and body composition of Asian Indians with metabolic

- syndrome: a randomized double-blind control trial, *Lipids Health Dis.*, 2017, **16**, 113.
- 84 F. Askari, B. Rashidkhani and A. Hekmatdoost, Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients, *Nutr. Res.*, 2014, **34**, 143–148.
 - 85 O. Markey, C. M. McClean, P. Medlow, G. W. Davison, T. R. Trinick, E. Duly and A. Shafat, Effect of cinnamon on gastric emptying, arterial stiffness, postprandial lipemia, glycemia, and appetite responses to high-fat breakfast, *Cardiovasc. Diabetol.*, 2011, **10**, 78.
 - 86 S. M. Blevins, M. J. Leyva, J. Brown, J. Wright, R. H. Scofield and C. E. Aston, Effect of cinnamon on glucose and lipid levels in non insulin-dependent type 2 diabetes, *Diabetes Care*, 2007, **30**, 2236–2237.
 - 87 K. Mnafigui, A. Derbali, S. Sayadi, N. Gharsallah, A. Elfeki and N. Allouche, Anti-obesity and cardioprotective effects of cinnamic acid in high fat diet- induced obese rats, *J. Food Sci. Technol.*, 2015, **52**, 4369–4377.
 - 88 I. N. Nayak, R. Chinta and R. Jetty, Anti-Atherosclerotic Potential of Aqueous Extract of Cinnamomum Zeylanicum Bark against Glucocorticoid Induced Atherosclerosis in Wistar Rats, *J. Clin. Diagnostic Res.*, 2017, **11**, FC19–FC23.
 - 89 B. H. Cheng, L. Y. Sheen and S. T. Chang, Hypolipidemic effects of S-(+)-linalool and essential oil from Cinnamomum osmophloeum ct. linalool leaves in mice, *J. Tradit. Complement. Med.*, 2018, **8**, 46–52.
 - 90 B. P. Lopes, T. G. Gaique, L. L. Souza, G. S. Paula, G. E. Kluck, G. C. Atella, A. C. Gomes, N. K. Simas, R. M. Kuster, T. M. Ortega-Carvalho, C. C. Pazos-Moura and K. J. Oliveira, Cinnamon extract improves the body composition and attenuates lipogenic processes in the liver and adipose tissue of rats, *Food Funct.*, 2015, **6**, 3257–3265.
 - 91 N. H. Kopp, S. Mukherjee and J. W. Yun, Trans-Cinnamic Acid Stimulates White Fat Browning and Activates Brown Adipocytes, *Nutrients*, 2019, **11**, 577.
 - 92 C. Kopp, S. P. Singh, P. Regenhard, U. Muller, H. Sauerwein and M. Mielenz, Trans-cinnamic acid increases adiponectin and the phosphorylation of AMP-activated protein kinase through G-protein-coupled receptor signaling in 3 T3-L1 adipocytes, *Int. J. Mol. Sci.*, 2014, **15**, 2906–2915.
 - 93 S. H. Kim and S. Y. Choung, Antihyperglycemic and anti-hyperlipidemic action of Cinnamomi Cassiae (Cinnamon bark) extract in C57BL/Ks db/db mice, *Arch. Pharmacol. Res.*, 2010, **33**, 325–333.
 - 94 P. Khare, S. Jagtap, Y. Jain, R. K. Baboota, P. Mangal, R. K. Boparai, K. K. Bhutani, S. S. Sharma, L. S. Premkumar, K. K. Kondepudi, K. Chopra and M. Bishnoi, Cinnamaldehyde supplementation prevents fasting-induced hyperphagia, lipid accumulation, and inflammation in high-fat diet-fed mice, *Biofactors*, 2016, **42**, 201–211.
 - 95 B. Qin, M. M. Polansky and R. A. Anderson, Cinnamon extract regulates plasma levels of adipose-derived factors and expression of multiple genes related to carbohydrate metabolism and lipogenesis in adipose tissue of fructose-fed rats, *Horm. Metab. Res.*, 2010, **42**, 187–193.
 - 96 A. Handberg, K. Levin, K. Hojlund and H. Beck-Nielsen, Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance, *Circulation*, 2006, **114**, 1169–1176.
 - 97 M. M. Hussain, J. Shi and P. Dreizen, Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly, *J. Lipid Res.*, 2003, **44**, 22–32.
 - 98 B. Qin, M. M. Polansky, Y. Sato, K. Adeli and R. A. Anderson, Cinnamon extract inhibits the postprandial overproduction of apolipoprotein B48-containing lipoproteins in fructose-fed animals, *J. Nutr. Biochem.*, 2009, **20**, 901–908.
 - 99 B. Qin, H. D. Dawson, N. W. Schoene, M. M. Polansky and R. A. Anderson, Cinnamon polyphenols regulate multiple metabolic pathways involved in insulin signaling and intestinal lipoprotein metabolism of small intestinal enterocytes, *Nutrition*, 2012, **28**, 1172–1179.
 - 100 N. Kaur, H. Chugh, V. Tomar, M. K. Sakharkar, S. K. Dass and R. Chandra, Cinnamon attenuates adiposity and affects the expression of metabolic genes in Diet-Induced obesity model of zebrafish, *Artif. Cells, Nanomed., Biotechnol.*, 2019, **47**, 2930–2939.
 - 101 A. R. Tall, Plasma cholesteryl ester transfer protein, *J. Lipid Res.*, 1993, **34**, 1255–1274.
 - 102 S. Lee, J. M. Han, H. Kim, E. Kim, T. S. Jeong, W. S. Lee and K. H. Cho, Synthesis of cinnamic acid derivatives and their inhibitory effects on LDL-oxidation, acyl-CoA:cholesterol acyltransferase-1 and -2 activity, and decrease of HDL-particle size, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 4677–4681.
 - 103 Z. Tuzcu, C. Orhan, N. Sahin, V. Juturu and K. Sahin, Cinnamon Polyphenol Extract Inhibits Hyperlipidemia and Inflammation by Modulation of Transcription Factors in High-Fat Diet-Fed Rats, *Oxid. Med. Cell. Longevity*, 2017, **2017**, 1583098.
 - 104 C. Gorrini, I. S. Harris and T. W. Mak, Modulation of oxidative stress as an anticancer strategy, *Nat. Rev. Drug Discovery*, 2013, **12**, 931–947.
 - 105 U. Forstermann, N. Xia and H. Li, Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis, *Circ. Res.*, 2017, **120**, 713–735.
 - 106 J. S. Lee, S. M. Jeon, E. M. Park, T. L. Huh, O. S. Kwon, M. K. Lee and M. S. Choi, Cinnamate supplementation enhances hepatic lipid metabolism and antioxidant defense systems in high cholesterol-fed rats, *J. Med. Food*, 2003, **6**, 183–191.
 - 107 H. Zhao, M. Zhang, F. Zhou, W. Cao, L. Bi, Y. Xie, Q. Yang and S. Wang, Cinnamaldehyde ameliorates LPS-induced cardiac dysfunction via TLR4-NOX4 pathway: The regulation of autophagy and ROS production, *J. Mol. Cell. Cardiol.*, 2016, **101**, 11–24.

- 108 P. Wang, Y. Yang, D. Wang, Q. Yang, J. Wan, S. Liu, P. Zhou and Y. Yang, Cinnamaldehyde Ameliorates Vascular Dysfunction in Diabetic Mice by Activating Nrf2, *Am. J. Hypertens.*, 2020, **33**, 610–619.
- 109 J. Maher and M. Yamamoto, The rise of antioxidant signaling—the evolution and hormetic actions of Nrf2, *Toxicol. Appl. Pharmacol.*, 2010, **244**, 4–15.
- 110 M. C. Flynn, G. Pernes, M. K. S. Lee, P. R. Nagareddy and A. J. Murphy, Monocytes, Macrophages, and Metabolic Disease in Atherosclerosis, *Front. Pharmacol.*, 2019, **10**, 666.
- 111 D. Wang, Y. Yang, Y. Lei, N. T. Tzvetkov, X. Liu, A. W. K. Yeung, S. Xu and A. G. Atanasov, Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products, *Pharmacol. Rev.*, 2019, **71**, 596–670.
- 112 V. V. Kunjathoor, M. Febbraio, E. A. Podrez, K. J. Moore, L. Andersson, S. Koehn, J. S. Rhee, R. Silverstein, H. F. Hoff and M. W. Freeman, Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages, *J. Biol. Chem.*, 2002, **277**, 49982–49988.
- 113 H. Kang, S. H. Park, J. M. Yun, T. G. Nam, Y. E. Kim, D. O. Kim and Y. J. Kim, Effect of cinnamon water extract on monocyte-to-macrophage differentiation and scavenger receptor activity, *BMC Complementary Altern. Med.*, 2014, **14**, 90.
- 114 B. H. Kim, Y. G. Lee, J. Lee, J. Y. Lee and J. Y. Cho, Regulatory effect of cinnamaldehyde on monocyte/macrophage-mediated inflammatory responses, *Mediators Inflammation*, 2010, **2010**, 529359.
- 115 G. R. Geovanini and P. Libby, Atherosclerosis and inflammation: overview and updates, *Clin. Sci.*, 2018, **132**, 1243–1252.
- 116 A. Solanki, L. K. Bhatt and T. P. Johnston, Evolving targets for the treatment of atherosclerosis, *Pharmacol. Ther.*, 2018, **187**, 1–12.
- 117 D. Tousoulis, E. Oikonomou, E. K. Economou, F. Crea and J. C. Kaski, Inflammatory cytokines in atherosclerosis: current therapeutic approaches, *Eur. Heart J.*, 2016, **37**, 1723–1732.
- 118 F. Shishehbor, M. R. Safar, E. Rajaei and M. H. Haghighizadeh, Cinnamon Consumption Improves Clinical Symptoms and Inflammatory Markers in Women With Rheumatoid Arthritis, *J. Am. Coll. Nutr.*, 2018, 1–6, DOI: 10.1080/07315724.2018.1460733.
- 119 M. Davari, R. Hashemi, P. Mirmiran, M. Hedayati, S. Sahranavard, S. Bahreini, R. Tavakoly and B. Talaei, Effects of cinnamon supplementation on expression of systemic inflammation factors, NF-kB and Sirtuin-1 (SIRT1) in type 2 diabetes: a randomized, double blind, and controlled clinical trial, *Nutr. J.*, 2020, **19**, 1.
- 120 P. Mirmiran, M. Davari, R. Hashemi, M. Hedayati, S. Sahranavard, S. Bahreini, R. Tavakoly and B. Talaei, A randomized controlled trial to determining the effect of cinnamon on the plasma levels of soluble forms of vascular adhesion molecules in type 2 diabetes mellitus, *Eur. J. Clin. Nutr.*, 2019, **73**, 1605–1612.
- 121 B. C. Liao, C. W. Hsieh, Y. C. Liu, T. T. Tzeng, Y. W. Sun and B. S. Wung, Cinnamaldehyde inhibits the tumor necrosis factor- α -induced expression of cell adhesion molecules in endothelial cells by suppressing NF-kappaB activation: effects upon IkappaB and Nrf2, *Toxicol. Appl. Pharmacol.*, 2008, **229**, 161–171.
- 122 S. C. Lee, S. Y. Wang, C. C. Li and C. T. Liu, Anti-inflammatory effect of cinnamaldehyde and linalool from the leaf essential oil of *Cinnamomum osmophloeum* Kanehira in endotoxin-induced mice, *J. Food Drug Anal.*, 2018, **26**, 211–220.
- 123 A. Schink, K. Naumoska, Z. Kitanovski, C. J. Kampf, J. Frohlich-Nowoisky, E. Thines, U. Poschl, D. Schuppan and K. Lucas, Anti-inflammatory effects of cinnamon extract and identification of active compounds influencing the TLR2 and TLR4 signaling pathways, *Food Funct.*, 2018, **9**, 5950–5964.
- 124 C. Pannee, I. Chandhanee and L. Wacharee, Antiinflammatory effects of essential oil from the leaves of *Cinnamomum cassia* and cinnamaldehyde on lipopolysaccharide-stimulated J774A.1 cells, *J. Adv. Pharm. Technol. Res.*, 2014, **5**, 164–170.
- 125 H. Cao, J. F. Urban Jr. and R. A. Anderson, Cinnamon polyphenol extract affects immune responses by regulating anti- and proinflammatory and glucose transporter gene expression in mouse macrophages, *J. Nutr.*, 2008, **138**, 833–840.
- 126 J. A. DiDonato, F. Mercurio and M. Karin, NF-kappaB and the link between inflammation and cancer, *Immunol. Rev.*, 2012, **246**, 379–400.
- 127 S. H. Lee, S. Y. Lee, D. J. Son, H. Lee, H. S. Yoo, S. Song, K. W. Oh, D. C. Han, B. M. Kwon and J. T. Hong, Inhibitory effect of 2'-hydroxycinnamaldehyde on nitric oxide production through inhibition of NF-kappa B activation in RAW 264.7 cells, *Biochem. Pharmacol.*, 2005, **69**, 791–799.
- 128 J. C. Liao, J. S. Deng, C. S. Chiu, W. C. Hou, S. S. Huang, P. H. Shie and G. J. Huang, Anti-Inflammatory Activities of *Cinnamomum cassia* Constituents In Vitro and In Vivo, *Evidence-Based Complementary Altern. Med.*, 2012, **2012**, 429320.
- 129 W. Li, W. Zhi, J. Zhao, W. Li, L. Zang, F. Liu and X. Niu, Cinnamaldehyde attenuates atherosclerosis via targeting the IkappaB/NF-kappaB signaling pathway in high fat diet-induced ApoE(-/-) mice, *Food Funct.*, 2019, **10**, 4001–4009.
- 130 B. C. Liao, C. W. Hsieh, Y. C. Lin and B. S. Wung, The glutaredoxin/glutathione system modulates NF-kappaB activity by glutathionylation of p65 in cinnamaldehyde-treated endothelial cells, *Toxicol. Sci.*, 2010, **116**, 151–163.
- 131 J. W. Hong, G. E. Yang, Y. B. Kim, S. H. Eom, J. H. Lew and H. Kang, Anti-inflammatory activity of cinnamon water extract in vivo and in vitro LPS-induced models, *BMC Complementary Altern. Med.*, 2012, **12**, 237.

- 132 M. R. Bennett, S. Sinha and G. K. Owens, Vascular Smooth Muscle Cells in Atherosclerosis, *Circ. Res.*, 2016, **118**, 692–702.
- 133 N. E. Buglak, W. Jiang and E. S. M. Bahnson, Cinnamic aldehyde inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in Zucker Diabetic Fatty rats, *Redox Biol.*, 2018, **19**, 166–178.
- 134 W. Li, W. Zhi, J. Zhao, Q. Yao, F. Liu and X. Niu, Cinnamaldehyde protects VSMCs against ox-LDL-induced proliferation and migration through S arrest and inhibition of p38, JNK/MAPKs and NF-kappaB, *Vasc. Pharmacol.*, 2018, **108**, 57–66.
- 135 L. Ouyang, K. Zhang, J. Chen, J. Wang and H. Huang, Roles of platelet-derived growth factor in vascular calcification, *J. Cell. Physiol.*, 2018, **233**, 2804–2814.
- 136 H. Kwon, J. J. Lee, J. H. Lee, W. K. Cho, M. J. Gu, K. J. Lee and J. Y. Ma, Cinnamon and its Components Suppress Vascular Smooth Muscle Cell Proliferation by Up-Regulating Cyclin-Dependent Kinase Inhibitors, *Am. J. Chin. Med.*, 2015, **43**, 621–636.
- 137 A. Sachinidis, R. Locher, W. Vetter, D. Tatje and J. Hoppe, Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells, *J. Biol. Chem.*, 1990, **265**, 10238–10243.
- 138 T. J. Kim and Y. P. Yun, Antiproliferative activity of NQ304, a synthetic 1,4-naphthoquinone, is mediated via the suppressions of the PI3 K/Akt and ERK1/2 signaling pathways in PDGF-BB-stimulated vascular smooth muscle cells, *Vasc. Pharmacol.*, 2007, **46**, 43–51.
- 139 Y. H. Jin and S. A. Kim, 2-Methoxycinnamaldehyde inhibits the TNF-alpha-induced proliferation and migration of human aortic smooth muscle cells, *Int. J. Mol. Med.*, 2017, **39**, 191–198.
- 140 J. Yeung, W. Li and M. Holinstat, Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases, *Pharmacol. Rev.*, 2018, **70**, 526–548.
- 141 J. Huang, S. Wang, X. Luo, Y. Xie and X. Shi, Cinnamaldehyde reduction of platelet aggregation and thrombosis in rodents, *Thromb. Res.*, 2007, **119**, 337–342.
- 142 H. Matsuda, R. Matsuda, S. Fukuda, H. Shiimoto and M. Kubo, Anti-thrombotic actions of 70% methanolic extract and cinnamic aldehyde from cinnamomi cortex, *Chem. Pharm. Bull.*, 1987, **35**, 1275–1280.
- 143 S. Y. Kim, Y. K. Koo, J. Y. Koo, T. M. Ngoc, S. S. Kang, K. Bae, Y. S. Kim and H. S. Yun-Choi, Platelet anti-aggregation activities of compounds from *Cinnamomum cassia*, *J. Med. Food*, 2010, **13**, 1069–1074.
- 144 S. M. Yu, T. S. Wu and C. M. Teng, Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor, *Br. J. Pharmacol.*, 1994, **111**, 906–912.
- 145 T. Sinnathamby, J. Yun, M. E. Clavet-Lanthier, C. Cheong and M. G. Sirois, VEGF and angiopoietins promote inflammatory cell recruitment and mature blood vessel formation in murine sponge/Matrigel model, *J. Cell. Biochem.*, 2015, **116**, 45–57.
- 146 H. L. Lin, L. Zhang, C. X. Liu, X. S. Xu, M. X. Tang, H. X. Lv, C. J. Li, H. W. Sun, M. Zhang, J. Hong and Y. Zhang, Haemin-enhanced expression of haem oxygenase-1 stabilizes erythrocyte-induced vulnerable atherosclerotic plaques, *Br. J. Pharmacol.*, 2010, **160**, 1484–1495.
- 147 E. C. Kim, H. J. Kim and T. J. Kim, Water extract of *Cinnamomum cassia* suppresses angiogenesis through inhibition of VEGF receptor 2 phosphorylation, *Biosci., Biotechnol., Biochem.*, 2015, **79**, 617–624.
- 148 R. R. Bansode, T. Leung, P. Randolph, L. L. Williams and M. Ahmedna, Cinnamon extract inhibits angiogenesis in zebrafish and human endothelial cells by suppressing VEGFR1, VEGFR2, and PKC-mediated MAP kinase, *Food Sci. Nutr.*, 2013, **1**, 74–82.
- 149 X. Yuan, L. Han, P. Fu, H. Zeng, C. Lv, W. Chang, R. S. Runyon, M. Ishii, L. Han, K. Liu, T. Fan, W. Zhang and R. Liu, Cinnamaldehyde accelerates wound healing by promoting angiogenesis via up-regulation of PI3 K and MAPK signaling pathways, *Lab. Invest.*, 2018, **98**, 783–798.
- 150 R. Akilen, Z. Pimlott, A. Tsiami and N. Robinson, Effect of short-term administration of cinnamon on blood pressure in patients with prediabetes and type 2 diabetes, *Nutrition*, 2013, **29**, 1192–1196.
- 151 T. N. Ziegenfuss, J. E. Hofheins, R. W. Mendel, J. Landis and R. A. Anderson, Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women, *J. Int. Soc. Sports Nutr.*, 2006, **3**, 45–53.
- 152 R. Akilen, A. Tsiami, D. Devendra and N. Robinson, Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: a randomized, placebo-controlled, double-blind clinical trial, *Diabet. Med.*, 2010, **27**, 1159–1167.
- 153 J. Wainstein, N. Stern, S. Heller and M. Boaz, Dietary cinnamon supplementation and changes in systolic blood pressure in subjects with type 2 diabetes, *J. Med. Food*, 2011, **14**, 1505–1510.
- 154 S. M. Mousavi, E. Karimi, M. Hajishafiee, A. Milajerdi, M. R. Amini and A. Esmailzadeh, Anti-hypertensive effects of cinnamon supplementation in adults: A systematic review and dose-response Meta-analysis of randomized controlled trials, *Crit. Rev. Food Sci. Nutr.*, 2020, **60**, 3144–3154.
- 155 H. G. Preuss, B. Echard, M. M. Polansky and R. Anderson, Whole cinnamon and aqueous extracts ameliorate sucrose-induced blood pressure elevations in spontaneously hypertensive rats, *J. Am. Coll. Nutr.*, 2006, **25**, 144–150.
- 156 P. Nyadjjeu, E. P. Ngudefack-Mbuyo, A. D. Atsamo, T. B. Ngudefack, A. B. Dongmo and A. Kamanyi, Acute and chronic antihypertensive effects of *Cinnamomum zeylanicum* stem bark methanol extract in L-NAME-induced hypertensive rats, *BMC Complementary Altern. Med.*, 2013, **13**, 27.
- 157 G. Raffai, B. Kim, S. Park, G. Khang, D. Lee and P. M. Vanhoutte, Cinnamaldehyde and cinnamaldehyde-

- containing micelles induce relaxation of isolated porcine coronary arteries: role of nitric oxide and calcium, *Int. J. Nanomed.*, 2014, **9**, 2557–2566.
- 158 L. Zhang, L. Wu, Y. Pan, L. Qin, T. Liu, X. Liu, H. Yoshitomi, K. Ikeda, H. Negishi, M. Gao, J. Li and T. Xu, Trans-cinnamaldehyde promotes nitric oxide release via the protein kinase-B /v-Akt murine thymoma viral oncogene -endothelial nitric oxide synthase pathway to alleviate hypertension in SHR.Cg-Leprcp/NDmcr rats, *J. Tradit. Chin. Med.*, 2018, **38**, 548–555.
 - 159 K. Mnafigui, A. Derbali, S. Sayadi, N. Gharsallah, A. Elfeki and N. Allouche, Anti-obesity and cardioprotective effects of cinnamic acid in high fat diet- induced obese rats, *J. Food Sci. Technol.*, 2015, **52**, 4369–4377.
 - 160 N. R. Tykocki, E. M. Boerman and W. F. Jackson, Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles, *Compr. Physiol.*, 2017, **7**, 485–581.
 - 161 J. Alvarez-Collazo, L. Alonso-Carbajo, A. I. Lopez-Medina, Y. A. Alpizar, S. Tajada, B. Nilius, T. Voets, J. R. Lopez-Lopez, K. Talavera, M. T. Perez-Garcia and J. L. Alvarez, Cinnamaldehyde inhibits L-type calcium channels in mouse ventricular cardiomyocytes and vascular smooth muscle cells, *Pflugers Arch.*, 2014, **466**, 2089–2099.
 - 162 Z. Wang, D. Ye, J. Ye, M. Wang, J. Liu, H. Jiang, Y. Xu, J. Zhang, J. Chen and J. Wan, The TRPA1 Channel in the Cardiovascular System: Promising Features and Challenges, *Front. Pharmacol.*, 2019, **10**, 1253.
 - 163 G. Pozsgai, J. V. Bodkin, R. Graepel, S. Bevan, D. A. Andersson and S. D. Brain, Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo, *Cardiovasc. Res.*, 2010, **87**, 760–768.
 - 164 T. J. Guzik and R. M. Touyz, Oxidative Stress, Inflammation, and Vascular Aging in Hypertension, *Hypertension*, 2017, **70**, 660–667.
 - 165 A. Singh, S. A. Khan, R. Choudhary and S. H. Bodakhe, Cinnamaldehyde Attenuates Cataractogenesis via Restoration of Hypertension and Oxidative Stress in Fructose-Fed Hypertensive rats, *J. Pharmacopuncture*, 2016, **19**, 137–144.
 - 166 G. W. Reed, J. E. Rossi and C. P. Cannon, Acute myocardial infarction, *Lancet*, 2017, **389**, 197–210.
 - 167 D. J. Hausenloy and D. M. Yellon, Myocardial ischemia-reperfusion injury: a neglected therapeutic target, *J. Clin. Invest.*, 2013, **123**, 92–100.
 - 168 M. Sedighi, A. Nazari, M. Faghihi, M. Rafieian-Kopaei, A. Karimi, M. Moghimian, S. A. Mozaffarpur, M. Rashidipour, M. Namdari, M. Cheraghi and B. Rasouljan, Protective effects of cinnamon bark extract against ischemia-reperfusion injury and arrhythmias in rat, *Phytother. Res.*, 2018, **32**, 1983–1991.
 - 169 J. S. Hwa, Y. C. Jin, Y. S. Lee, Y. S. Ko, Y. M. Kim, L. Y. Shi, H. J. Kim, J. H. Lee, T. M. Ngoc, K. H. Bae, Y. S. Kim and K. C. Chang, 2-methoxycinnamaldehyde from *Cinnamomum cassia* reduces rat myocardial ischemia and reperfusion injury in vivo due to HO-1 induction, *J. Ethnopharmacol.*, 2012, **139**, 605–615.
 - 170 S. Li, X. Sun, H. Wu, P. Yu, X. Wang, Z. Jiang, E. Gao, J. Chen, D. Li, C. Qiu, B. Song, K. Chen, K. He, D. Yang and Y. Yang, TRPA1 Promotes Cardiac Myofibroblast Transdifferentiation after Myocardial Infarction Injury via the Calcineurin-NFAT-DYRK1A Signaling Pathway, *Oxid. Med. Cell. Longevity*, 2019, **2019**, 6408352.
 - 171 A. Pollack, A. R. Kontorovich, V. Fuster and G. W. Dec, Viral myocarditis—diagnosis, treatment options, and current controversies, *Nat. Rev. Cardiol.*, 2015, **12**, 670–680.
 - 172 Y. Zhang, W. Cao, Y. H. Xie, Q. Yang, X. Q. Li, X. X. Liu and S. W. Wang, The comparison of alpha-bromo-4-chlorocinnamaldehyde and cinnamaldehyde on coxsackie virus B3-induced myocarditis and their mechanisms, *Int. Immunopharmacol.*, 2012, **14**, 107–113.
 - 173 M. Gyongyosi, J. Winkler, I. Ramos, Q. T. Do, H. Firat, K. McDonald, A. Gonzalez, T. Thum, J. Diez, F. Jaisser, A. Pizard and F. Zannad, Myocardial fibrosis: biomedical research from bench to bedside, *Eur. J. Heart Fail.*, 2017, **19**, 177–191.
 - 174 L. L. Kang, D. M. Zhang, C. H. Ma, J. H. Zhang, K. K. Jia, J. H. Liu, R. Wang and L. D. Kong, Cinnamaldehyde and allopurinol reduce fructose-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4/6-IRAK4/1 signaling to suppress NLRP3 inflammasome activation, *Sci. Rep.*, 2016, **6**, 27460.
 - 175 B. M. Leon and T. M. Maddox, Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research, *World J. Diabetes*, 2015, **6**, 1246–1258.
 - 176 K. E. Bornfeldt, Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture, *Diabetes*, 2015, **64**, 2689–2697.
 - 177 A. American Diabetes, Diagnosis and classification of diabetes mellitus, *Diabetes Care*, 2013, **36**(Suppl 1), S67–S74.
 - 178 N. H. Cho, J. E. Shaw, S. Karuranga, Y. Huang, J. D. da Rocha Fernandes, A. W. Ohlrogge and B. Malanda, IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045, *Diabetes Res. Clin. Pract.*, 2018, **138**, 271–281.
 - 179 N. Kleefstra, S. J. Logtenberg, K. H. Groenier and H. J. Bilo, Cinnamon in glycaemic control: systematic review and meta analysis, *Clin. Nutr.*, 2012, **31**, 776, author reply 777.
 - 180 Q. Jia, X. Liu, X. Wu, R. Wang, X. Hu, Y. Li and C. Huang, Hypoglycemic activity of a polyphenolic oligomer-rich extract of *Cinnamomum parthenoxylon* bark in normal and streptozotocin-induced diabetic rats, *Phytomedicine*, 2009, **16**, 744–750.
 - 181 R. W. Allen, E. Schwartzman, W. L. Baker, C. I. Coleman and O. J. Phung, Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis, *Ann. Fam. Med.*, 2013, **11**, 452–459.

- 182 S. Gupta, S. B. Sharma, S. K. Bansal and K. M. Prabhu, Antihyperglycemic and hypolipidemic activity of aqueous extract of *Cassia auriculata* L. leaves in experimental diabetes, *J. Ethnopharmacol.*, 2009, **123**, 499–503.
- 183 K. Vijayakumar, B. Prasanna, R. L. Rengarajan, A. Rathinam, S. Velayuthaprabhu and A. V. Anand, Anti-diabetic and hypolipidemic effects of Cinnamon cassia bark extracts: an in vitro, in vivo, and in silico approach, *Arch. Physiol. Biochem.*, 2020, 1–11, DOI: 10.1080/13813455.2020.1822415.
- 184 S. Kirkham, R. Akilen, S. Sharma and A. Tsiami, The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance, *Diabetes Obes. Metab.*, 2009, **11**, 1100–1113.
- 185 K. Im, A. Issac, J. Nm, E. Ninan, B. Maliakel and R. Kuttan, Effects of the polyphenol content on the anti-diabetic activity of *Cinnamomum zeylanicum* extracts, *Food Funct.*, 2014, **5**, 2208–2220.
- 186 J. Jitomir and D. S. Willoughby, Cassia cinnamon for the attenuation of glucose intolerance and insulin resistance resulting from sleep loss, *J. Med. Food*, 2009, **12**, 467–472.
- 187 E. J. Verspohl, K. Bauer and E. Neddermann, Antidiabetic effect of *Cinnamomum cassia* and *Cinnamomum zeylanicum* in vivo and in vitro, *Phytother. Res.*, 2005, **19**, 203–206.
- 188 K. Couturier, C. Batandier, M. Awada, I. Hininger-Favier, F. Canini, R. A. Anderson, X. Leverve and A. M. Roussel, Cinnamon improves insulin sensitivity and alters the body composition in an animal model of the metabolic syndrome, *Arch. Biochem. Biophys.*, 2010, **501**, 158–161.
- 189 R. I. Holt, H. L. Simpson and P. H. Sonksen, The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis, *Diabet. Med.*, 2003, **20**, 3–15.
- 190 A. R. Saltiel and C. R. Kahn, Insulin signalling and the regulation of glucose and lipid metabolism, *Nature*, 2001, **414**, 799–806.
- 191 K. A. A. Mohammed, H. M. S. Ahmed, H. A. Sharaf, A. A. El-Nekeety, S. H. Abdel-Aziem, F. M. Mehaya and M. A. Abdel-Wahhab, Encapsulation of cinnamon oil in whey protein counteracts the disturbances in biochemical parameters, gene expression, and histological picture of the liver and pancreas of diabetic rats, *Environ. Sci. Pollut. Res. Int.*, 2020, **27**, 2829–2843.
- 192 H. Cao, M. M. Polansky and R. A. Anderson, Cinnamon extract and polyphenols affect the expression of tripartite, insulin receptor, and glucose transporter 4 in mouse 3 T3-L1 adipocytes, *Arch. Biochem. Biophys.*, 2007, **459**, 214–222.
- 193 C. Cardillo, S. S. Nambi, C. M. Kilcoyne, W. K. Choucair, A. Katz, M. J. Quon and J. A. Panza, Insulin stimulates both endothelin and nitric oxide activity in the human forearm, *Circulation*, 1999, **100**, 820–825.
- 194 J. R. Petrie, S. Ueda, D. J. Webb, H. L. Elliott and J. M. Connell, Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease, *Circulation*, 1996, **93**, 1331–1333.
- 195 M. Montagnani, L. V. Ravichandran, H. Chen, D. L. Esposito and M. J. Quon, Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells, *Mol. Endocrinol.*, 2002, **16**, 1931–1942.
- 196 G. Zeng, F. H. Nystrom, L. V. Ravichandran, L. N. Cong, M. Kirby, H. Mostowski and M. J. Quon, Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells, *Circulation*, 2000, **101**, 1539–1545.
- 197 B. Qin, M. Nagasaki, M. Ren, G. Bajotto, Y. Oshida and Y. Sato, Cinnamon extract prevents the insulin resistance induced by a high-fructose diet, *Horm. Metab. Res.*, 2004, **36**, 119–125.
- 198 L. Sylow, M. Kleinert, C. Pehmoller, C. Prats, T. T. Chiu, A. Klip, E. A. Richter and T. E. Jensen, Akt and Rac1 signaling are jointly required for insulin-stimulated glucose uptake in skeletal muscle and downregulated in insulin resistance, *Cell. Signal.*, 2014, **26**, 323–331.
- 199 M. E. Abdelmageed, G. S. Shehatou, R. A. Abdelsalam, G. M. Suddek and H. A. Salem, Cinnamaldehyde ameliorates STZ-induced rat diabetes through modulation of IRS1/PI3 K/AKT2 pathway and AGEs/RAGE interaction, *Naunyn Schmiedeberg's Arch. Pharmacol.*, 2019, **392**, 243–258.
- 200 J. E. Li, K. Futawaka, H. Yamamoto, M. Kasahara, T. Tagami, T. H. Liu and K. Moriyama, Cinnamaldehyde Contributes to Insulin Sensitivity by Activating PPARdelta, PPARgamma, and RXR, *Am. J. Chin. Med.*, 2015, **43**, 879–892.
- 201 R. M. Hafizur, A. Hameed, M. Shukrana, S. A. Raza, S. Chishti, N. Kabir and R. A. Siddiqui, Cinnamic acid exerts anti-diabetic activity by improving glucose tolerance in vivo and by stimulating insulin secretion in vitro, *Phytomedicine*, 2015, **22**, 297–300.
- 202 H. Cao, D. J. Graves and R. A. Anderson, Cinnamon extract regulates glucose transporter and insulin-signaling gene expression in mouse adipocytes, *Phytomedicine*, 2010, **17**, 1027–1032.
- 203 C. Kopp, S. P. Singh, P. Regenhard, U. Muller, H. Sauerwein and M. Mielenz, Trans-cinnamic acid increases adiponectin and the phosphorylation of AMP-activated protein kinase through G-protein-coupled receptor signaling in 3 T3-L1 adipocytes, *Int. J. Mol. Sci.*, 2014, **15**, 2906–2915.
- 204 S. Camacho, S. Michlig, C. de Senarclens-Bezencon, J. Meylan, J. Meystre, M. Pezzoli, H. Markram and J. le Coutre, Anti-obesity and anti-hyperglycemic effects of cinnamaldehyde via altered ghrelin secretion and functional impact on food intake and gastric emptying, *Sci. Rep.*, 2015, **5**, 7919.
- 205 D. Liu, H. Gao, W. Tang and S. Nie, Plant non-starch polysaccharides that inhibit key enzymes linked to type 2 diabetes mellitus, *Ann. N. Y. Acad. Sci.*, 2017, **1401**, 28–36.

- 206 S. H. Kim, S. H. Hyun and S. Y. Choung, Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice, *J. Ethnopharmacol.*, 2006, **104**, 119–123.
- 207 H. M. S. Shihabudeen, D. H. Priscilla and K. Thirumurugan, Cinnamon extract inhibits alpha-glucosidase activity and dampens postprandial glucose excursion in diabetic rats, *Nutr. Metab.*, 2011, **8**, 46.
- 208 S. Adisakwattana, O. Lersuwankij, U. Poputtachai, A. Minipun and C. Suparpprom, Inhibitory activity of cinnamon bark species and their combination effect with acarbose against intestinal alpha-glucosidase and pancreatic alpha-amylase, *Plant Foods Hum. Nutr.*, 2011, **66**, 143–148.
- 209 P. Ercan and S. N. El, Inhibitory effects of bioaccessible anthocyanins and procyanidins from apple, red grape, cinnamon on alpha-amylase, alpha-glucosidase and lipase, *Int. J. Vitam. Nutr. Res.*, 2021, **91**, 16–24.
- 210 D. M. Cheng, P. Kuhn, A. Poulev, L. E. Rojo, M. A. Lila and I. Raskin, In vivo and in vitro antidiabetic effects of aqueous cinnamon extract and cinnamon polyphenol-enhanced food matrix, *Food Chem.*, 2012, **135**, 2994–3002.
- 211 T. Sartorius, A. Peter, N. Schulz, A. Drescher, I. Bergheim, J. Machann, F. Schick, D. Siegel-Axel, A. Schurmann, C. Weigert, H. U. Haring and A. M. Hennige, Cinnamon extract improves insulin sensitivity in the brain and lowers liver fat in mouse models of obesity, *PLoS One*, 2014, **9**, e92358.
- 212 G. W. Gould, H. M. Thomas, T. J. Jess and G. I. Bell, Expression of human glucose transporters in *Xenopus* oocytes: kinetic characterization and substrate specificities of the erythrocyte, liver, and brain isoforms, *Biochemistry*, 1991, **30**, 5139–5145.
- 213 K. Tobe, R. Suzuki, M. Aoyama, T. Yamauchi, J. Kamon, N. Kubota, Y. Terauchi, J. Matsui, Y. Akanuma, S. Kimura, J. Tanaka, M. Abe, J. Ohsumi, R. Nagai and T. Kadowaki, Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver, *J. Biol. Chem.*, 2001, **276**, 38337–38340.
- 214 X. Xia, J. Yan, Y. Shen, K. Tang, J. Yin, Y. Zhang, D. Yang, H. Liang, J. Ye and J. Weng, Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis, *PLoS One*, 2011, **6**, e16556.
- 215 M. Legan, S. Tevzic, A. Tolar, B. Luzar and V. F. Marolt, Glucose transporter-1 (GLUT-1) immunoreactivity in benign, premalignant and malignant lesions of the gallbladder, *Pathol. Oncol. Res.*, 2011, **17**, 61–66.
- 216 P. Anand, K. Y. Murali, V. Tandon, P. S. Murthy and R. Chandra, Insulinotropic effect of cinnamaldehyde on transcriptional regulation of pyruvate kinase, phosphoenolpyruvate carboxykinase, and GLUT4 translocation in experimental diabetic rats, *Chem. Biol. Interact.*, 2010, **186**, 72–81.
- 217 Y. Shen, M. Fukushima, Y. Ito, E. Muraki, T. Hosono, T. Seki and T. Ariga, Verification of the antidiabetic effects of cinnamon (*Cinnamomum zeylanicum*) using insulin-uncontrolled type 1 diabetic rats and cultured adipocytes, *Biosci., Biotechnol., Biochem.*, 2010, **74**, 2418–2425.
- 218 Q. Yang, T. E. Graham, N. Mody, F. Preitner, O. D. Peroni, J. M. Zabolotny, K. Kotani, L. Quadro and B. B. Kahn, Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes, *Nature*, 2005, **436**, 356–362.
- 219 T. E. Graham, Q. Yang, M. Bluher, A. Hammarstedt, T. P. Ciaraldi, R. R. Henry, C. J. Wason, A. Oberbach, P. A. Jansson, U. Smith and B. B. Kahn, Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects, *N. Engl. J. Med.*, 2006, **354**, 2552–2563.
- 220 W. Zhang, Y. C. Xu, F. J. Guo, Y. Meng and M. L. Li, Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus, *Chin. Med. J.*, 2008, **121**, 2124–2128.
- 221 B. Roffey, A. Atwal and S. Kubow, Cinnamon water extracts increase glucose uptake but inhibit adiponectin secretion in 3 T3-L1 adipose cells, *Mol. Nutr. Food Res.*, 2006, **50**, 739–745.
- 222 J. Li, T. Liu, L. Wang, X. Guo, T. Xu, L. Wu, L. Qin and W. Sun, Antihyperglycemic and antihyperlipidemic action of cinnamaldehyde in C57BLKS/J db/db mice, *J. Tradit. Chin. Med.*, 2012, **32**, 446–452.
- 223 Y. Shen, N. Honma, K. Kobayashi, L. N. Jia, T. Hosono, K. Shindo, T. Ariga and T. Seki, Cinnamon extract enhances glucose uptake in 3 T3-L1 adipocytes and C2C12 myocytes by inducing LKB1-AMP-activated protein kinase signaling, *PLoS One*, 2014, **9**, e87894.
- 224 S. Qusti, H. A. El Rabey and S. A. Balashram, The Hypoglycemic and Antioxidant Activity of Cress Seed and Cinnamon on Streptozotocin Induced Diabetes in Male Rats, *Evidence-Based Complementary Altern. Med.*, 2016, **2016**, 5614564.
- 225 R. P. Robertson and J. S. Harmon, Pancreatic islet beta-cell and oxidative stress: the importance of glutathione peroxidase, *FEBS Lett.*, 2007, **581**, 3743–3748.
- 226 F. Hu, F. Guo, Y. Zhu, Q. Zhou, T. Li, H. Xiang and D. Shang, IL-17 in pancreatic disease: pathogenesis and pharmacotherapy, *Am. J. Cancer Res.*, 2020, **10**, 3551–3564.
- 227 P. Drikvandi, S. Bahramikia and M. Alirezaei, Modulation of the antioxidant defense system in liver, kidney, and pancreas tissues of alloxan-induced diabetic rats by camphor, *J. Food Biochem.*, 2020, **44**, e13527.
- 228 S. Kumar, N. Vasudeva and S. Sharma, GC-MS analysis and screening of antidiabetic, antioxidant and hypolipidemic potential of *Cinnamomum tamala* oil in streptozotocin induced diabetes mellitus in rats, *Cardiovasc. Diabetol.*, 2012, **11**, 95.
- 229 P. Sun, T. Wang, L. Chen, B. W. Yu, Q. Jia, K. X. Chen, H. M. Fan, Y. M. Li and H. Y. Wang, Trimer procyanidin oligomers contribute to the protective effects of cinnamon extracts on pancreatic beta-cells in vitro, *Acta Pharmacol. Sin.*, 2016, **37**, 1083–1090.

- 230 A. A. Hosni, A. A. Abdel-Moneim, E. S. Abdel-Reheim, S. M. Mohamed and H. Helmy, Cinnamaldehyde potentially attenuates gestational hyperglycemia in rats through modulation of PPARgamma, proinflammatory cytokines and oxidative stress, *Biomed. Pharmacother.*, 2017, **88**, 52–60.
- 231 S. C. Lee, W. X. Xu, L. Y. Lin, J. J. Yang and C. T. Liu, Chemical composition and hypoglycemic and pancreas-protective effect of leaf essential oil from indigenous cinnamon (*Cinnamomum osmophloeum* Kanehira), *J. Agric. Food Chem.*, 2013, **61**, 4905–4913.
- 232 J. A. Hebda and A. D. Miranker, The interplay of catalysis and toxicity by amyloid intermediates on lipid bilayers: insights from type II diabetes, *Annu. Rev. Biophys.*, 2009, **38**, 125–152.
- 233 R. A. Ritzel and P. C. Butler, Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis, *Diabetes*, 2003, **52**, 1701–1708.
- 234 L. Jiao, X. Zhang, L. Huang, H. Gong, B. Cheng, Y. Sun, Y. Li, Q. Liu, L. Zheng and K. Huang, Proanthocyanidins are the major anti-diabetic components of cinnamon water extract, *Food Chem. Toxicol.*, 2013, **56**, 398–405.
- 235 H. Ping, G. Zhang and G. Ren, Antidiabetic effects of cinnamon oil in diabetic KK-Ay mice, *Food Chem. Toxicol.*, 2010, **48**, 2344–2349.
- 236 M. Van Hul, L. Geurts, H. Plovier, C. Druart, A. Everard, M. Stahlman, M. Rhimi, K. Chira, P. L. Teissedre, N. M. Delzenne, E. Maguin, A. Guilbot, A. Brochot, P. Gerard, F. Backhed and P. D. Cani, Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier, *Am. J. Physiol. Endocrinol. Metab.*, 2018, **314**, E334–E352.
- 237 H. Zhao, H. Wu, M. Duan, R. Liu, Q. Zhu, K. Zhang and L. Wang, Cinnamaldehyde Improves Metabolic Functions in Streptozotocin-Induced Diabetic Mice by Regulating Gut Microbiota, *Drug Des. Devel. Ther.*, 2021, **15**, 2339–2355.
- 238 R. Singh, A. Barden, T. Mori and L. Beilin, Advanced glycation end-products: a review, *Diabetologia*, 2001, **44**, 129–146.
- 239 N. J. Hayward, G. J. McDougall, S. Farag, J. W. Allwood, C. Austin, F. Campbell, G. Horgan and V. Ranawana, Cinnamon Shows Antidiabetic Properties that Are Species-Specific: Effects on Enzyme Activity Inhibition and Starch Digestion, *Plant Foods Hum. Nutr.*, 2019, **74**, 544–552.
- 240 P. Muthenna, G. Raghu, P. A. Kumar, M. V. Surekha and G. B. Reddy, Effect of cinnamon and its procyanidin-B2 enriched fraction on diabetic nephropathy in rats, *Chem. Biol. Interact.*, 2014, **222**, 68–76.
- 241 P. Muthenna, G. Raghu, C. Akileshwari, S. N. Sinha, P. Suryanarayana and G. B. Reddy, Inhibition of protein glycation by procyanidin-B2 enriched fraction of cinnamon: delay of diabetic cataract in rats, *IUBMB Life*, 2013, **65**, 941–950.
- 242 H. Zheng, S. A. Whitman, W. Wu, G. T. Wondrak, P. K. Wong, D. Fang and D. D. Zhang, Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy, *Diabetes*, 2011, **60**, 3055–3066.
- 243 Y. M. Yan, P. Fang, M. T. Yang, N. Li, Q. Lu and Y. X. Cheng, Anti-diabetic nephropathy compounds from *Cinnamomum cassia*, *J. Ethnopharmacol.*, 2015, **165**, 141–147.
- 244 A. Mishra, R. Bhatti, A. Singh and M. P. S. Ishar, Ameliorative effect of the cinnamon oil from *Cinnamomum zeylanicum* upon early stage diabetic nephropathy, *Planta Med.*, 2010, **76**, 412–417.
- 245 H. M. El-Bassossy, A. Fahmy and D. Badawy, Cinnamaldehyde protects from the hypertension associated with diabetes, *Food Chem. Toxicol.*, 2011, **49**, 3007–3012.
- 246 A. Jawale, A. K. Datusalia, M. Bishnoi and S. S. Sharma, Reversal of diabetes-induced behavioral and neurochemical deficits by cinnamaldehyde, *Phytomedicine*, 2016, **23**, 923–930.
- 247 A. A. Hemmati, S. Alboghobeish and A. Ahangarpour, Effects of cinnamic acid on memory deficits and brain oxidative stress in streptozotocin-induced diabetic mice, *Korean J. Physiol. Pharmacol.*, 2018, **22**, 257–267.
- 248 C. Sampath, J. C. Sprouse, M. L. Freeman and P. R. Gangula, Activation of Nrf2 attenuates delayed gastric emptying in obesity induced diabetic (T2DM) female mice, *Free Radicals Biol. Med.*, 2019, **135**, 132–143.
- 249 A. Daemi, M. Lotfi, M. R. Farahpour, A. Oryan, S. J. Ghayour and A. Sonboli, Topical application of *Cinnamomum* hydroethanolic extract improves wound healing by enhancing re-epithelialization and keratin biosynthesis in streptozotocin-induced diabetic mice, *Pharm. Biol.*, 2019, **57**, 799–806.
- 250 R. Zare, A. Nadjarzadeh, M. M. Zarshenas, M. Shams and M. Heydari, Efficacy of cinnamon in patients with type II diabetes mellitus: A randomized controlled clinical trial, *Clin. Nutr.*, 2019, **38**, 549–556.
- 251 B. Mang, M. Wolters, B. Schmitt, K. Kelb, R. Lichtinghagen, D. O. Stichtenoth and A. Hahn, Effects of a cinnamon extract on plasma glucose, HbA_{1c}, and serum lipids in diabetes mellitus type 2, *Eur. J. Clin. Invest.*, 2006, **36**, 340–344.
- 252 T. Lu, H. Sheng, J. Wu, Y. Cheng, J. Zhu and Y. Chen, Cinnamon extract improves fasting blood glucose and glycosylated hemoglobin level in Chinese patients with type 2 diabetes, *Nutr. Res.*, 2012, **32**, 408–412.
- 253 J. C. G. L. Neto, M. M. C. Damasceno, M. A. Ciol, R. de Freitas, M. F. M. de Araujo, C. R. S. Teixeira, G. C. N. Carvalho, K. Lisboa, R. L. L. Marques, A. Alencar and M. L. Zanetti, Efficacy of Cinnamon as an Adjuvant in Reducing the Glycemic Biomarkers of Type 2 Diabetes Mellitus: A Three-Month, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial, *J. Am. Coll. Nutr.*, 2021, 1–9, DOI: 10.1080/07315724.2021.1878967.

- 254 M. J. Leach and S. Kumar, Cinnamon for diabetes mellitus, *Cochrane Database Syst. Rev.*, 2012, (9), CD007170.
- 255 J. A. Altschuler, S. J. Casella, T. A. MacKenzie and K. M. Curtis, The effect of cinnamon on A1C among adolescents with type 1 diabetes, *Diabetes Care*, 2007, **30**, 813–816.
- 256 B. Talaei, A. Amouzegar, S. Sahranavard, M. Hedayati, P. Mirmiran and F. Azizi, Effects of Cinnamon Consumption on Glycemic Indicators, Advanced Glycation End Products, and Antioxidant Status in Type 2 Diabetic Patients, *Nutrients*, 2017, **9**, 991.
- 257 M. Dorri, S. Hashemitabar and H. Hosseinzadeh, Cinnamon (*Cinnamomum zeylanicum*) as an antidote or a protective agent against natural or chemical toxicities: a review, *Drug Chem. Toxicol.*, 2018, **41**, 338–351.